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ABSTRACT 
Background: Tested independently, studies report that obesity and HIV infection and/or ART 
use in pregnancy are associated with adverse birth outcomes. However, there is limited data on 
the combined impact of these maternal factors on adverse birth outcomes. Given the high 
prevalence of obesity and HIV infection in Sub-Saharan Africa (SSA), understanding these 
associations is important. This study examined the association of the double burden of high 
maternal body mass index and HIV infection/ART use in pregnancy with adverse birth 
outcomes.   
 
Methods: Part A of this mini-dissertation presents the study protocol which outlines the 
rationale, aim and objectives of the study; the research methodology, analysis plan and ethical 
considerations. Part B is the literature review of studies conducted in SSA which investigated 
the relationship between BMI and HIV infection and adverse birth outcomes of interest. Part C 
is the journal-formatted manuscript which presents the results and discussion of the study 
findings in relation to other scholars. The referencing style used for the whole thesis is 
Vancouver as required by the journal chosen for the formatting of the manuscript. 
 
We used data collected from a large observational Prematurity Study that enrolled HIV-infected 
and HIV-uninfected women seeking antenatal care at Gugulethu MOU in Cape Town between 
April 2015 and October 2016. A subset of HIV-infected women who booked early (≤24weeks) 
was prospectively followed through delivery and was used to study gestational weight gain 
(GWG) and adverse birth outcomes. Data was obtained from review of medical records and 
study questionnaires. Logistic regression was used to compare birth outcomes by BMI status: 
preterm delivery (PTD), low/high birthweight (LBW/HBW) and small/large gestational age 
(SGA/LGA) between HIV-uninfected and -infected women; and between HIV-infected women 
who initiated ART before pregnancy and those who initiated ART during pregnancy. Using the 
subset of HIV-infected women who booked early (≤24weeks), we compared the adverse birth 
outcomes between low, adequate and high GWG.  
 
Results: Of the 2779 participants included in the analysis, 20% had normal BMI, 29% were 
overweight, 51% were obese and 39% were HIV-infected. Overall, there was no association 
between obese BMI and PTD (aOR 1.06, 95% CI 0.75-1.49). Instead, obese BMI was 
negatively associated with LBW (aOR 0.53; CI: 0.39-0.72) and SGA infants (aOR 0.55, 95% 
CI 0.41-0.75) compared to normal BMI women. Stratifying by HIV infection showed similar 
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results for LBW (aOR 0.54; CI: 0.35-0.83) and SGA (aOR 0.60, 95% CI 0.38-0.94) in obese 
HIV-infected women compared to corresponding women with normal BMI. However, 
comparison of obese HIV-uninfected and obese HIV-infected women showed a higher 
incidence of LBW and SGA infants in obese HIV-infected women (12% vs 8%). The 
association of obese BMI and LBW and SGA in HIV-infected women did not differ by timing 
of ART initiation.    
 
In terms of HBW and LGA, overall, obese BMI was positively associated with HBW (aOR 
2.00; CI: 1.13-3.57) and LGA infants (aOR 1.98, 95% CI 1.40-2.80) compared to normal BMI 
women. Stratifying by HIV infection also showed a positive association between obese BMI 
and HBW (aOR 2.54; CI: 1.17-5.53) and LGA (aOR 2.30; CI: 1.46-3.62) in HIV-uninfected 
women. Although a similar positive association was also obtained in obese HIV-infected 
women, the strength of this association was weaker for both HBW (aOR 1.41; CI: 0.59-3.34) 
and LGA (aOR 1.58; CI: 0.91-2.72). When the analysis was restricted to HIV-infected women 
by timing of ART initiation we found that obese women who initiated ART during pregnancy 
had 3-fold likelihood of having LGA infants (aOR 3.26; CI: 1.32-8.09) and those who initiated 
ART before pregnancy had a reversed effect (aOR 0.87; CI: 0.43-1.78) compared to respective 
normal BMI women. However, restricting the analysis to obese HIV-infected women only 
revealed a counter effect of the two conditions where the frequencies of both LGA and SGA 
are high. Abnormal gestational weight gain had no association with PTD, LBW, HBW and 
SGA. However, we showed that GWG lower than the IOM recommended values reduced the 
likelihood of having LGA infants (aOR 0.29; CI: 0.12-0.70) compared to adequate GWG. 
 
Conclusions: Obese HIV-infected women appear to be cushioned by their BMI against LBW 
and SGA when compared to normal BMI. However, comparison of these outcomes amongst 
women who are either obese or HIV-infected reveal a higher burden of both SGA and LGA 
infants in obese HIV-infected women, regardless of ART initiation status. 
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1. INTRODUCTION 
1.1 Background 
Over the years, there has been a growing concern regarding the increasing global prevalence of 
obesity. Obesity is a risk factor for type II diabetes, hypertension, heart disease and some 
cancers (1, 2). Ironically, there is a belief that overweight and obesity prevalence is highest in 
developed countries due to consumption of Western foods rich in fat/sugar and increased 
sedentary lifestyle (3). However, it is developing countries that have doubled the burden of 
chronic non-communicable diseases due to upward shift in obesity prevalence, particularly in 
Africa (4). Body fat is estimated by body mass index (BMI) which is individual’s weight in 
relation to their squared height. Standard BMI classification by the World Health Organisation 
(WHO) include underweight (≤18.5 kg/m2), normal weight (18.5-24.9 kg/m2), overweight (25-
29.9 kg/m2) and obese (≥30 kg/m2) people (5).  
 
The Demographic and Health Survey reported that South Africa is the most obese region in 
Sub-Saharan Africa (SSA) with approximately 68% women being either overweight or obese, 
and one in five being severely obese (BMI ≥35.0 kg/m2) (6). As a result, most women reach 
their reproductive age (15 - 49 years) with high BMI (defined as either overweight or obesity). 
In pregnancy, women tend to further gain weight due to overeating and foetus weight; this is 
known as gestational weight gain (GWG). Recent studies show that women with high pre-
pregnancy BMI are likely to have increased GWG compared to those who have normal weight; 
and both these factors have adverse maternal and infant health outcomes (7, 8). For this reason, 
the Institute of Medicine (IOM) came up with recommended ranges for GWG based on WHO 
BMI categories (Table 1) to allow monitoring of weight gain during pregnancy by health 
practitioners to identify women at high risk for adverse health outcomes (9, 10). 
 
Table 1. Institute of Medicine gestational weight gain guidelines (9) 
Pre-pregnancy BMI Total weight gain  
Underweight (<18.5 kg/m2) 12.5 – 18 kg 
Normal weight (18.5 – 24.9 kg/m2) 11.5 – 16 kg 
Overweight (25.0 – 29.9 kg/m2) 7 – 11.5 kg 
Obese (≥30.0 kg/m2) 5 – 9 kg 
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The table above shows the WHO classification of BMI categories from underweight to obese 
individuals, next to each BMI category is the IOM recommended weight gain during the entire 
pregnancy period. For example, people who are in the overweight category should only gain an 
additional total weight of 7-11.5 kg during pregnancy, if they fail to reach or if they exceed this 
range, they will be at high risk of adverse pregnancy and birth outcomes (9). 
 
In addition to being the most obese region in SSA, South Africa has the highest prevalence of 
human immunodeficiency virus (HIV) infection. Similar to high BMI burden, the majority of 
adults living with HIV infection are women aged between 18-30 years, an age range that 
coincides with their peak reproductive years (11). Maternal HIV infection and long-term use of 
antiretroviral therapy (ART) during pregnancy have been reported to be associated with an 
increased risk of adverse birth outcomes (12-16). HIV infection and ART-related adverse birth 
outcomes include preterm delivery (PTD), low birth weight (LBW) and small size for 
gestational age (SGA) infants (13-17).  
 
Similarly, the specific birth outcomes associated with high BMI and GWG that have been 
interrogated in the literature include PTD, LBW (18-20) and other outcomes such as high 
birthweight (HBW) also known as macrosomia (birthweight >4kg) (21, 22), intrauterine growth 
restriction (IUGR), caesarean section delivery (23), preterm rupture of membranes, post-term 
births (24), stillbirth, miscarriage, large for gestational age (LGA) infants, Apgar score of <7 at 
5 minutes, neonatal intensive care admissions, early neonatal death  and congenital 
abnormalities (22, 25-27). 
 
Preterm delivery is the leading cause of neonatal mortality and morbidity worldwide (28). 
Although some studies have reported a protective effect of maternal BMI against PTD (29, 30), 
others suggests that high BMI increases PTD via intrapartum complications such as pre-
eclampsia, gestational diabetes and hypertension (19, 31). On the other hand, HIV infection 
and/or ART use are said to mediate PTD via systemic immune activation and inflammation 
(32-34). With the increasing number of women being initiated on ART in pregnancy due to 
WHO universal test and treat (UTT) guidelines (35), the consequences of the combination of 
long-term ART use and high BMI on maternal and child health are currently not clear. 
Therefore, quantification of harmful effects of obesity in pregnant women using ART is of 
public health importance in our setting. 
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1.2 Rationale 
Obesity is a growing public health concern because of the increased number of women who 
reach childbearing age with high BMI. Data from high income countries has shown that high 
BMI is associated with adverse birth outcomes. In Africa, there is growing evidence sharing 
the association between ART use in pregnancy and adverse birth outcomes, resulting in long-
term child morbidity (15, 16, 36). Given the high prevalence of both obesity and HIV infection 
in women of child-bearing age, it is important to investigate the combined association of these 
factors in pregnant women. In South Africa, a preliminary analysis of a study conducted in 
Gugulethu on adverse birth outcomes has shown that there is high prevalence of obesity among 
HIV-infected women seeking antenatal care (ANC). However, the influence of this observation 
on birth outcomes has not been analysed. Therefore, this study will investigate the association 
of high BMI and GWG with adverse birth outcomes by HIV status and timing of ART initiation 
in this cohort. The specific outcomes of interest are PTD, LBW, HBW, SGA and LGA. 
2. AIM AND OBJECTIVES  
2.1 Aim  
The aim of this study is to examine the association between high BMI (overweight and obese) 
and gestational weight gain (GWG) and adverse birth outcomes in women seeking antenatal 
care (ANC) at Gugulethu Maternity Obstetric Unit (MOU) in Cape Town, South Africa. 
2.2 Objectives  
• To describe the prevalence of high BMI among pregnant women seeking ANC; 
• To examine the association between high BMI at first ANC booking and adverse birth 
outcomes by HIV and ART status; and 
• To examine the association between gestational weight gain (GWG) and adverse birth 
outcomes in a subset of HIV-infected women who booked early (≤ 24 weeks). 
 
3. METHODOLOGY  
3.1 Study Design  
This study will be a secondary data analysis of data collected from a large observational cohort 
titled: “The Prematurity Immunology in HIV-infected Mothers and their infants Study (PIMS)". 
The overall aim of the parent study is to quantify the association between ART use in pregnancy 
and adverse birth outcomes in Cape Town, South Africa. The overall cohort of the parent study 
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includes all women booking for their first ANC between April 2015 and October 2016.  A 
subset of these women, who booked early (≤24weeks) and were HIV-infected were enrolled 
into a prospective cohort study with intensive measurement through pregnancy to 12-month 
postpartum period.  
 
3.2 Study Setting 
This study is taking place in the Gugulethu community, which has a population of 
approximately 98 468 residents (37). The residents of Gugulethu are predominantly of a low 
socioeconomic status with an average monthly income of ≤R3 200 (37).  The Gugulethu MOU 
serves this population by providing antenatal, obstetric and infant care for low risk pregnancies 
to approximately 5 000 women per annum. Women with history of pregnancy complications or 
who require specialist care are referred to secondary (Mowbray Maternity Hospital) or tertiary 
(Groote Schuur Hospital) level obstetric facilities. This is particularly important for this current 
study as high BMI and GWG is associated with pregnancy complications which could require 
deliveries in these facilities.  
 
3.3 Study Population and Sampling 
A total of 3 254 pregnant women aged 18 years and above were enrolled into the parent study 
between April 2015 and October 2016. A subset of 550 women who booked early (≤24 weeks) 
were enrolled into the prospective cohort. 
 
3.4 Data Collection  
3.4.1 Exposures of Interest 
For maternal BMI, data will be abstracted into the study form (Appendix 4B) from the maternity 
case records (MCR) as weight and height measurements are performed routinely by clinic 
nurses in all women attending their first ANC. Baseline BMI will be calculated as weight 
divided by the square of height. The limitation of not having pre-pregnancy BMI will be 
corrected by adjusting for length of gestation at first booking in the analysis (38, 39). For the 
first comparison (Assessment A), BMI will be categorised based on WHO standards: 
• Normal BMI (18.5-24.9 kg/m2) 
• Overweight (25-29.9 kg/m2)  
• Obese (≥30 kg/m2)  
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For maternal GWG, data will be obtained from study case report forms (CRFs) as weight 
measurements are performed by trained study personnel during the follow-up period of ≤24 
weeks to 12 months post-partum (Appendix 4D). Total GWG will be calculated as the 
difference in the weight obtained from the third trimester visit and weight at enrolment. For the 
second comparison (Assessment B), GWG will be categorised based on IOM standards as 
shown in (Table 1): 
• Low (< IOM) 
• Adequate GWG (= IOM) 
• High GWG (>IOM) 
The information regarding HIV/ART status will be obtained from the MCR study form 
(Appendix 4B) and will be categorised as:  
• ART initiated before pregnancy 
• ART initiated during pregnancy  
 
3.4.2 Outcomes of Interest 
For adverse birth outcomes, obstetric data will be collected into the obstetric study form 
(Appendix 4C) from MCR and from infant clinic card (Appendix 4E) for the prospective cohort 
participants.  
• Gestational age (GA) at delivery 
Gestational age at delivery will be categorized into term (≥37) and PTD (<37 weeks). 
• Birth weight 
Birthweight will be categorized into low (<2500g), normal (2500 - 3999g) and high birth 
weight (≥4000g). 
• Size for gestational age 
Size for gestational age will be categorized into small (SGA: <10th percentile), appropriate 
(AGA: 10-90th percentile) and large (LGA: >90th percentile) for gestational age infants based 
on INTERGROWTH-21st Project Standards (40, 41). 
All the exposure and outcome variables to be included in the analysis are shown in table 2 
below. 
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Table 2. Variables to be included in the analysis 
Variable Scale Categories 
Maternal   
Age (years) Numerical – continuous 
Categorical – ordinal 
Mean/median 
<20, 20-24, 25-29, 30-34, ≥35 
Height (cm) Numerical – continuous 
Categorical – ordinal 
Mean/median 
<155, 156-161, ≥162 
BMI  Numerical – continuous 
Categorical – ordinal 
Mean/median  
Normal, Overweight, Obese 
In a relationship Categorical – binary Yes, No 
Completed High School  Categorical – binary Yes, No 
GA at enrolment Numerical – continuous 
Categorical – ordinal 
Mean/median  
1st, 2nd, 3rd trimester 
Parity Numerical – continuous 
Categorical – ordinal 
Mean/median  
1, 2, ≥3 
Gravidity Numerical – continuous 
Categorical – ordinal 
Mean/median  
0, 1, ≥2 
Total GWG Numerical – continuous 
Categorical – ordinal 
Mean/median 
Low, adequate and high  
HIV status Categorical – binary HIV-infected, HIV-uninfected 
ART status Categorical – binary ART initiation before and 
during pregnancy 
 
Infant   
GA at delivery (weeks) Categorical – binary Term (≥37), PTD (<37) 
Birth weight (g) Numerical – continuous 
Categorical – ordinal 
Mean/median  
Low (<2500), normal (2500 - 
3999g), high (≥4000g)  
Size for gestational age Categorical – ordinal Small (SGA), appropriate 
(AGA), large (LGA) 
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3.5 Data Management and Analysis Plan 
3.5.1 Data Safety 
The data collected from the parent study is captured into Microsoft Access database, has 
automated daily backups to prevent loss and is password protected. Password protection ensures 
that access to the participant information is restricted to the data manager, principal investigator 
and study coordinator. The file does not have participant names but only study participant 
numbers as identifiers. 
 
3.5.2 Data Analysis  
All data will be analysed using STATA Version 14 (Stata Corporation, College Station, Texas 
USA). Continuous variables will be summarised using means/standard deviation (SD) or 
median/interquartile based on normality distribution. Categorical variables will be summarised 
using counts/proportions. Statistical significance (p<0.05) between groups (BMI: normal, 
overweight and obesity; GWG: low, adequate and high) will be determined using Chi-squared 
or Kruskal Wallis test.  
 
To assess the association of high BMI and GWG with adverse birth outcomes, multivariable 
logistic regression models will be fitted against each of the outcomes of interest using WHO 
normal BMI and IOM adequate weight gain as reference values. The analysis will first be 
conducted in the whole sample, then will be stratified by HIV status and further by ART status. 
All results will be presented as adjusted Odds Ratios (aOR) with 95% confidence intervals (CI). 
Models will be adjusted for potential confounders identified a priori including maternal age, 
GA at enrolment, parity, gravidity and prior PTD (42).  
 
4. ETHICAL CONSIDERATIONS 
The parent study was approved by the University of Cape Town Faculty of Health Sciences 
Research Ethics Committee (UCT-HREC) (739/2014) (Appendix 2B) and the University of 
Southampton Institutional Review Board (12542 PIMS) (Appendix 2C). Ethical approval for 
this proposed study will be sought from the UCT-HREC.  
 
4.1 Informed Consent 
Informed consent for the parent study was obtained from the participants prior to enrolment; 
additional consent regarding access to participant clinical records was also obtained (Appendix 
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3A and 3B). This study will use the consented data and therefore does not require additional 
consent from the participants.  
 
4.2 Privacy and Confidentiality 
To ensure confidentiality, participants are assigned a 5-digit identifier number which is used in 
all study documents. Participant folders are kept in locked cabinets to restrict access. The 
electronic data is password-protected and only the data manager, principal investigator and 
study coordinator have access to this information. This proposed study will use the original 
participant identifiers from the parent study and the results obtained will be reported as an 
average to ensure confidentiality. 
 
4.3 Risks and Benefits 
There are no particular risks posed by this study except for the provision of sometimes sensitive 
information of which is still protected because there is no use of participant names on the CRFs. 
There are no direct benefits of this study to participants except that they have access to study 
ultrasound and are given a transfer letter to relevant physician if there are any medical concerns 
regarding maternal or infant health. Over long term, there will be indirect benefit of improving 
maternal and child health outcomes in Cape Town. For example, the results of the current study 
will give an insight into the association of high BMI and GWG with birth outcomes by HIV 
and ART status, and relevant recommendations will be made available to the Gugulethu 
Community health centre management. 
 
4.4 Reporting and Implementation 
Study findings will be reported in a manuscript that will be submitted in peer-reviewed journal 
which will be approved by all study stakeholders. Data will also be presented in local and 
international conferences, meetings, workshops and to the management of the Gugulethu MOU. 
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4.5 Logistics 
Table 3. Study Timeline 
Activity Time (months) 
Mar-Apr 18 May-Jun 18 Jul-Aug 18 Sept 18 Oct 18 
Protocol submission 
to Ethics 
     
Merge and clean data      
 
Data analysis      
 
Thesis and manuscript 
write-up  
     
Finalise thesis and 
submit for marking 
     
Submit manuscript for 
publication 
     
 
4.6 Budget 
Data analysis will be conducted as part of an MPH degree and no payment for the student is 
required. 
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1. INTRODUCTION 
Currently, approximately 7 000 new-born infants die every day, contributing to 46% of all 
under-5 child mortality (1). The majority of neonatal deaths are due to direct and indirect 
complications of PTD and SGA births which are both associated with LBW (2). Despite a 
significant reduction of new-born mortality due to the prioritisation of child health by global 
health agencies in year 2000, South Africa and other low-middle income countries failed to 
meet the required target of two-third reduction in 2015 (3). After 2015, the new sustainable 
development goals (SGD) to be achieved by 2030 were set, goal 3 aims to ‘Ensure healthy lives 
and promote well-being for all at all ages’; including a specific target of reducing the neonatal 
mortality rate to 12 deaths per 1 000 live births (4). Therefore, to achieve this goal, accelerated 
efforts are required; especially in SSA where reductions have been slower.  
 
Adverse maternal health is directly responsible for poor child health outcomes. A study 
conducted by Slyker at al.(5) in Kenyan women found that poor maternal health is associated 
with PTD, SGA and LBW infants, resulting in 6-fold increased risk of neonatal death. 
Consequently, any interventions targeting maternal risk factors for these causes of neonatal 
death can have significant impact in improving neonatal health. One preventable maternal risk 
factor that can be targeted, due to it’s contribution on adverse birth outcomes is obesity, which 
is on the rise in SSA. 
 
Worldwide obesity prevalence has almost tripled since 1975 (6). In 2016, there were 
approximately 1.9 billion overweight and 650 million obese adults, with women being the 
majority compared to males (6). In South Africa, an alarming 68% of women of child-bearing 
age are overweight or obese (7). This is partly attributed to changing lifestyle from consumption 
of traditional foods to high fat and high sugar diet, accompanied by increased sedentary lifestyle 
(8-10). In addition, body weight perception and cultural beliefs of regarding chubby weight as 
being attractive among women in SSA is reported to be one of the strongest predictors of 
overweight and obesity (10, 11).  
 
Conflicting evidence exists regarding the association between high pregnancy BMI and adverse 
birth outcomes. Some studies report PTD, increased birth weight/macrosomia (≥4 kg) and LGA 
infants (12-14). Whereas, others report LBW and SGA infants due to intrauterine foetal growth 
restriction resulting from materno-foetal hypoperfusion in obese women (15-17). Other 
mechanisms implicated in weight-induced adverse birth outcomes are related to maternal 
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complications such as gestational hypertension, diabetes, pre-eclampsia, thromboembolism and 
urinary tract infections (18-21).  
 
Similar to high pregnancy BMI, HIV infection without treatment has been shown to be 
associated with adverse birth outcomes such as PTD, SGA and LBW infants (22-24). However, 
despite the availability of treatment, the previously observed adverse birth outcomes in women 
with untreated HIV infection persisted in women receiving treatment (25-28). Therefore, 
countries with a high burden of HIV/ART-use and obesity will be hindered from achieving the 
SDG3 target of reducing neonatal mortality rate to 12 deaths per 1 000 live births by 2030 (4). 
Although there is vast evidence on independent association of obesity with adverse birth 
outcomes; and of HIV infection and ART-use with adverse birth outcomes, there is limited data 
regarding the combined impact of both obesity and HIV on birth outcomes. Given the high 
prevalence of both HIV and obesity in SSA, it is critical to establish whether the combined 
association exists.  
 
2. AIM AND OBJECTIVES 
The aim of this literature review is to explore, appraise and synthesise literature on the 
association between high pregnancy BMI and adverse birth outcomes in HIV-infected women 
in SSA. Therefore, this review will focus on selected studies from SSA to identify gaps in the 
literature that require further research. However, data regarding the exposure and outcomes of 
interest will also be drawn from high income countries as obesity is a global public health 
concern.  
 
3. SEARCH METHOD 
Relevant articles were searched on online databases including PubMed, MEDLINE, EMBASE 
and EBSCO platform. Reference list of relevant articles and a general internet search was also 
conducted to identify more literature and reports from the global health agencies such as the 
WHO and IOM. The search key words used were a combination of obesity, gestational weight 
gain, adverse birth outcomes and HIV infection; together with their MeSH terms as shown 
below:  
• Obesity OR body mass index OR gestational weight change  
AND 
• Birth outcomes OR pregnancy outcomes 
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AND 
• HIV-infected OR antiretroviral therapy  
 
("obesity"[MeSH Terms] OR "obesity"[All Fields]) OR ("body mass index"[MeSH Terms] OR 
("body"[All Fields] AND "mass"[All Fields] AND "index"[All Fields]) OR "body mass 
index"[All Fields]) OR (gestational[All Fields] AND ("body weight changes"[MeSH Terms] 
OR ("body"[All Fields] AND "weight"[All Fields] AND "changes"[All Fields]) OR "body 
weight changes"[All Fields] OR ("weight"[All Fields] AND "change"[All Fields]) OR "weight 
change"[All Fields])) AND (("parturition"[MeSH Terms] OR "parturition"[All Fields] OR 
"birth"[All Fields]) AND outcomes[All Fields]) OR ("pregnancy outcome"[MeSH Terms] OR 
("pregnancy"[All Fields] AND "outcome"[All Fields]) OR "pregnancy outcome"[All Fields] 
OR ("pregnancy"[All Fields] AND "outcomes"[All Fields]) OR "pregnancy outcomes"[All 
Fields]) AND (antiretroviral[All Fields] AND ("therapy"[Subheading] OR "therapy"[All 
Fields] OR "therapeutics"[MeSH Terms] OR "therapeutics"[All Fields])) OR hiv-infected[All 
Fields] 
 
3.1 Inclusion and Exclusion Criteria 
The search was restricted to publications written in English. Only studies conducted in SSA 
were included for the review. Due to limited number of articles retrieved, there was no 
restriction on the publication or data collection years. The literature that was found relevant was 
published between years 1999 and 2018, and data was collected between 1992 and 2016. All 
study designs were included, the population of interest was HIV-infected (treated or untreated) 
and -uninfected pregnant adult women. The exposure of interest was pregnancy BMI and/or 
GWG; studies with either PTD, birth weight or size for gestational age as an outcome were 
included. All included studies are summarised in Tables 1a.  
 
4. QUALITY AND COMPARABILITY OF STUDIES 
A total of 357 articles were retrieved during the search of PubMed, MEDLINE, EMBASE and 
EBSCO platform. Following the screening of titles and abstracts, 132 articles were deemed 
irrelevant for the review because they did not have the three factors that this study is assessing; 
they either examined association between obesity and adverse birth outcomes or between ART-
use and adverse birth outcomes and not the combination of both exposures. After screening the 
methodology and full text of the remaining articles, 214 of them were excluded for various 
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reasons including irrelevant population, not conducted in SSA and absence of relevant 
comparison groups (Figure 1), leaving a total of 9 included articles from PubMed (22, 24, 29-
35). One additional article was obtained from review of reference lists of relevant publications 
(23) and 2 MMed theses were retrieved from EBSCO platform (36, 37), making a total of 12 
reviewed studies. The quality and comparability of all 12 studies was assessed based on study 
design, sample size and outcome assessment method as summarised in Table 1a and 1b. 
 
 
Figure 1. Flow diagram showing the selection process for the reviewed studies 
 
4.1 Study Design 
Out of the 12 eligible studies included in the review, 6 of them were observational cohort studies 
and the other 6 studies were randomized controlled trials (RCTs). Four out of the 6 
observational studies had prospective follow-up and were conducted in Rwanda, South Africa 
and Zambia (23, 29, 32, 36). These 4 studies enrolled participants at first trimester (<28 weeks 
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GA) (29, 32), second trimester (>28 weeks GA) (23) and during labour (36). Three out of the 
4 studies collected the exposure and outcome data from study measures such as questionnaires, 
anthropometric measurements and laboratory testing of collected specimens during different 
study visits (23, 29, 32). The other study used a combination of both study measures and 
abstraction of information from clinical records (36). The remaining 2 out of 6 observational 
studies had retrospective follow-up and were conducted in South Africa and Cameroon (30, 
37). One study enrolled participants that booked for their ANC during first trimester and used 
only medical records to collect data (37). The second retrospective study enrolled participants 
admitted in the labour ward at term and used both study measures and medical records for data 
collection (30). Unlike prospective studies which recruited women over a period of 1 year (23, 
29, 32, 36), retrospective studies selected women that booked over a narrow time period of 4 
months (30, 37).  
 
The 6 RCT studies were conducted across 4 SSA countries, with 5 of them enrolling women 
booking for their first ANC during first trimester (24, 31, 33-35). The remaining study enrolled 
participants who were in the third trimester (≥36 weeks) and those admitted at term in the labour 
ward (22). In contrast to observational studies that mostly had a single research site, the majority 
of RCT’s recruited participants from multiple sites (22, 24, 34), with the HPTN 024 trial 
recruiting in multiple countries over a 2 year period (33). Only one RCT was primarily designed 
to investigate the association of maternal nutrition status and adverse birth outcomes where the 
intervention was vitamin supplementation to improve poor micronutrients in Tanzanian women 
(24). The other 5 studies were secondary data analysis for trials that originally investigated the 
effectiveness of different ART regimens as prevention of mother-to-child-transmission 
(PMTCT) strategies in Zambia and Uganda (22, 31, 35); and antibiotic interventions for 
improvement of birth outcomes in Tanzania, Zambia and Malawi (33, 34). By nature of the 
design, all RCT studies collected exposure and outcome data through study measures involving 
questionnaires, anthropometric measurements and laboratory testing of collected specimens 
performed by trained study personnel and/or clinicians during different study visits.  
 
4.2 Sample Size 
Most observational studies had sample sizes below 500 with 5 studies having a range between 
91-437 (23, 29, 30, 32, 36) and the remaining study conducted in South Africa had 970 
participants (37). Two RCTs conducted in Uganda had small sample sizes of 158 and 356 (31, 
35); whereas 4 multicentre studies done in Tanzania, Zambia and Malawi had larger sample 
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sizes ranging from 1002-2149 participants (22, 24, 33, 34). In overall, the studies reviewed had 
sample sizes ranging from 91-2149. 
 
4.3 Outcome Assessment 
Eight studies reported preterm delivery as an outcome and 4 of them used the last menstrual 
period (LMP) to determine gestational age (24, 31, 33, 35). In addition to LMP, 2 of these 4 
studies used an ultrasonography (US) gestation if LMP was discordant with US (31, 35). 
Ultrasonography is not routinely available in public maternity clinics in which most of these 
studies were conducted. As a result, only the APPLe trial conducted in Malawi strictly used US 
as a method of GA assessment because their primary outcome was accurate determination of 
factors associated with PTD, early PTD and late PTD (34). The remaining 2 studies do not 
report the PTD assessment method that they used (29, 37), one of them only mention having 
abstracted infant outcomes from medical records (37). Two studies determined term vs PTD 
using Ballard and Finnstrom scores (23, 33). These scoring methods are based on neurological 
and physical examination of new born maturity parameters immediately after birth (38).  
 
Ten out of 12 studies reported birth weight as an outcome, with only 2 of them having study 
personnel who directly measured infant weight immediately after birth (23, 24). Four studies 
recorded birth weight from medical records  (30, 31, 36, 37) and the other 4 did not report how 
they obtained data for this outcome  (22, 29, 33, 35). In terms of size for gestational age, only 
3 out of the 12 studies reported this outcome (23, 24, 35). Size for gestational age is measured 
by comparing the infant’s GA, sex and their birth weight against standardised values to 
determine the percentile in which they fall in. The 3 studies used either LMP, US or Finnstrom 
score to determine the GA and direct measurement of infant weight by study clinicians (23, 24, 
35), with one study not reporting how the birth weight was obtained (35). 
 
4.4 Summary of Study Quality Appraisal 
The aim of this study is to determine the association between high maternal BMI and GWG and 
adverse birth outcomes by HIV and ART status. Therefore, the quality of studies synthesised 
in this review was determined based on the design that clearly defined overweight/obese group, 
recruited participants in first trimester to allow measurement of gestational weight changes; 
adequate sample size to detect differences between comparison groups, and clearly defined 
outcomes of interest. None of the reviewed studies met all the criteria, however Gadama (37), 
Fouelifack et al. (30) and Anderson et al. (29) were the closest. 
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5. RESULTS FROM STUDIES REVIEWED 
The results of the review of the included studies focuses on definitions and the association 
between exposures (high BMI and GWG) and adverse birth outcomes (PTD, LBW, HBW, SGA 
and LGA). The exposure/outcome definitions and key findings from the included studies are 
summarised in Tables 1b and 2, respectively.  
 
5.1 Exposure Definitions and Comparison Groups  
5.1.1 High Maternal BMI 
High BMI in this review refers to overweight and obese group of participants. All 6 
observational studies used standard, WHO-recommended BMI cut-offs of normal (18.5 - ≤24.9 
kg/m2), overweight (25.0 - ≤29.9 kg/m2) and (obese ≥30.0 kg/m2) categories for grouping 
participants. In contrast,  most RCTs grouped participants based on BMI quartiles (22, 24) and 
tertiles (33, 35) as shown in table 1b. The reason for categorising BMI based on quartiles and 
tertiles is that weight measurements vary greatly by week of gestation regardless of trimester 
(22, 24) and the unavailability of standard BMI categories for pregnant women (33, 35). As a 
result of such grouping, the categories of interest which are overweight and obese groups were 
not explicitly indicated in these RCTs. None of the 12 studies justify the use of first trimester 
BMI measurement as an equivalent for pre-pregnancy BMI. Studies in other settings have 
justified the use of first trimester BMI, as weight change in early pregnancy is negligible (21, 
39), while others use GA-adjusted BMI to approximate pre-pregnancy BMI (40, 41).  
 
5.1.2 High GWG 
Due to previous reports that have shown an association between GWG and adverse birth 
outcomes (42-44), 7 out of 12 studies investigated GWG as a risk factor for adverse birth 
outcomes in addition to baseline pregnancy BMI (24, 30-35). Two studies based weight gain 
on IOM weight gain recommendations, having sub-categories of inadequate, ideal and 
excessive weight gain without giving the numerical ranges (30, 32). The PROMOTE-Pregnant 
Women and Infants trial from Uganda had categories of low [<25th percentile (<0.1kg kg/wk)] 
vs high [≥25th percentile (≥0.1kg kg/wk)] weight gain (31, 35). Three studies had weight loss 
and weight gain categories (24, 33, 34); defined as weight loss (<0 kg/wk), low [0.01-0.18 (≤25 
percentile)], normal [0.19-0.41 (>25 - ≤75 percentile)] and high [≥0.42 (>75 percentile)] weight 
gain (33). Most studies recruited women at their first trimester and therefore used overall weight 
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changes calculated as a difference between weight at enrolment and weight at 3rd trimester; only 
one study reported weight gain and/or loss per trimester (24).  
 
5.1.3 HIV/ART Status 
Four studies had asymptomatic, untreated women who were given nevirapine (NVP) regimen 
during labour (22, 24, 33, 34), 2 sub-studies from the PROMOTE-Pregnant Women and Infants 
trial used ART-naïve women on protease inhibitor vs non-nucleoside reverse transcriptase 
inhibitor-based ART regimen (35) and on lopinavir/ritonavir vs efavirenz plus 
lamivudine/zidovudine (31). One study used participants who were not on treatment and some 
who were on highly active ART (HAART) with no specific regimen names; whereas 5 studies 
do not report whether the HIV-infected women received any treatment or not (23, 29, 30, 32, 
37). 
 
5.2 Outcome Definitions 
5.2.1 Preterm Delivery 
A total of 8 studies examined PTD as an outcome. The WHO defines preterm delivery as 
delivery that occurs before completion of the 37 weeks of gestation; with sub-categories of 
extreme PTD (< 28 weeks), very PTD (28 - 32 weeks) and moderate to late PTD (32 - 37 weeks) 
(45). Seven studies used the WHO clinical definition of <37 weeks delivery gestation (23, 24, 
29, 31, 33-35) with only one study not reporting the definition that they adopted (22). Some 
studies further sub-divided PTD into 2 categories of very PTD (<32 weeks) and PTD (<37 
weeks) (31), while the APPLe trial had 3 sub-categories of early (24-33 weeks), late (34-36 
weeks) and overall PTD (<37 weeks) (34). 
 
5.2.2 Birth Weight 
Ten studies reported birth weight as an outcome. The WHO categorises birth weight as low 
(<2500g), normal (2500-3999g) and large birth weight (≥4000g) (46, 47). Six studies defined 
LBW (23, 24, 29, 30, 33, 35) and macrosomia (30, 32, 37) using the standard WHO definitions, 
while 2 studies used continuous birth weight and reported mean birth weight (22, 36). 
 
5.2.3 Size for Gestational Age 
Size for gestational age is a measure of fetal growth based on gestation, sex and birth weight; 
and only 3 studies reported this outcome. There are no global standards for the categories of 
size for gestational age as this measure is based on specific population characteristics (48). Two 
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of them used the categories of SGA (<10th percentile), AGA (10 - 90th percentile) and LGA 
(>90th percentile) for the infant's gestational age based on USA standards (24, 35, 49). The third 
study reported IUGR and defined it as LBW with GA ≥ 37 weeks (23).  
 
5.3 Association Between High Pregnancy BMI and Adverse Birth Outcomes in the 
Context of HIV Infection and/or ART Use 
Many studies investigating the association of body weight and adverse birth outcomes in SSA 
focused on maternal malnutrition due to poverty and food insecurity affecting low income 
countries (50, 51). However, there has been a growing recognition of concurrent nutrition 
transition that has resulted in the rising epidemic of obesity. In Africa, obesity is reported to be 
>40% in women of reproductive age (52). Some studies report that the adverse birth outcomes 
associated with high BMI and GWG are HBW/macrosomia (≥4000g) and LGA infants (13, 53, 
54). The proposed mechanism for the influence of maternal obesity on foetal growth is 
gestational diabetes mellitus characterised by insulin resistance which leads to increased 
maternal glucose and triglycerides (17, 55). Since maternal blood is passed to the foetus via the 
placenta, the foetus also experiences high levels of insulin, glucose and triglycerides which all 
promote foetal growth (55, 56). Macrosomic new-born infants are at risk of neonatal death 
mediated by complications of hypoglycaemia, respiratory distress and hyperbilirubinaemia 
(57). As a result, hypoglycaemic agents were proposed as a potential intervention that could be 
given to pregnant mothers at increased risk of diabetes (13), although the effectiveness and 
cost-benefit in SSA requires further investigation. 
 
In contrast to macrosomia, other scholars report that high pregnancy BMI is associated with 
PTD, SGA and LBW and infants (14-16, 58, 59). The mechanism proposed for LBW and SGA 
in obese women is intrauterine foetal growth restriction mediated by reduced placental nutrient 
delivery due to reduced blood flow to the developing foetus (17). This materno-foetal hypo-
perfusion is partly due to vasoconstriction caused by reduced affinity between vascular 
endothelial growth factor and it’s receptor which inhibits the action of vasodilators (60, 61). In 
contrast, a study conducted in Cameroon did not observe any association between maternal 
BMI/GWG with LBW and macrosomia (30). However, the absence of association may have 
been due to the low prevalence of obesity (14% vs 49% normal weight) in the study population. 
 
In terms of PTD, it is important to consider the type of PTD between medically indicated (MI) 
and spontaneous delivery in obese women. Medically indicated PTD is a deliberate medical 
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induction of labour or caesarean section to deliver the baby due to maternal or foetal 
complications. Spontaneous PTD is a natural premature rupturing of foetal membranes 
(PROM) resulting in preterm labour. There is vast evidence regarding the association of high 
BMI with MI-PTD, where pre-eclampsia is the main risk factor for early caesarean section in 
these women (19, 62, 63). However, there is controversy regarding the association of high BMI 
with spontaneous PTD. Some scholars found a protective potential of obesity against 
spontaneous PTD due to reduced levels of spontaneous uterine activity in obese women 
compared to normal or underweight women (64); whereas a more recent study found increased 
risk of spontaneous rather than MI-PTD in obese women (65). The differences in these findings 
could be attributed to the different population of women used. For example, Ehrenberg et al. 
(64) who found less spontaneous PTD used women who were already at high risk of PTD based 
on previous experience and hence likely to have had medical indications that led them to 
experience more MI than spontaneous PTD. On the other hand, Sung et al. (65) who found 
increased spontaneous PTD used women who had twin pregnancies rather than singletons. 
Twin pregnancies have 3-fold likelihood of PROM compared to singleton pregnancies (66) and 
this could have resulted in higher rate of spontaneous PTD that was observed in the study. The 
proposed mechanism for spontaneous PTD in obese women is the increased production of 
maternal inflammatory proteins such as interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α) 
and IL-1β (17, 67). This inflammation is exacerbated by frequent genital and urinary tract 
infections in obese women, resulting in chorioamnionitis and increased risk of spontaneous 
PTD (19, 67).   
 
Adding complexity to the association between high BMI and adverse birth outcomes is HIV 
infection which is prevalent in similar population group of women of child bearing age. This 
double burden poses a challenge in understanding the association between high BMI and 
adverse birth outcomes in the context of HIV, since HIV infection and/or ART-use in pregnancy 
have also been shown to be associated with adverse birth outcomes (26, 28, 68). Early studies 
conducted prior to availability of HIV treatment in low-income countries showed that HIV 
infection was associated with maternal wasting, PTD and LBW infants (23, 24, 69). The 
mechanisms for maternal wasting in HIV-infected women was multifactorial including 
inadequate diet, intestinal malabsorption, metabolic disturbances and increased production of 
cytokines due to onset of opportunistic infections (70). This suggest that PTD during this period 
may have been due to opportunistic infections in the advanced HIV infection stage which 
consequently led to disturbance of immune system and premature labour. Whereas LBW infants 
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could have been due to insufficient nutrients delivered to the baby, resulting in foetal growth 
restriction.  
 
In the reviewed studies, 3 RCTs conducted between 1992-2003 in Tanzania, Zambia and 
Malawi which investigated birth outcomes of HIV-infected, untreated women had similar 
findings of greater risk of PTD, LBW and SGA linked to HIV infection-related weight loss and 
low BMI (22, 24, 33). The same conclusions are echoed in the APPLe trial conducted in Malawi 
which showed that low pre-pregnancy BMI and inadequate weight gain in pregnancy is 
associated with PTD while high BMI and weight gain improved these outcomes (34). As a 
result, some of these studies report increased maternal BMI as protective against these adverse 
birth outcomes (22, 24). In agreement, a micronutrient supplementation trial conducted in 
Tanzania showed that improved weight gain due to supplementation of vitamin B, C and E in 
HIV-infected women reduces PTD and LBW by almost 40% (71). However, these studies 
reporting high BMI to be protective did not indicate the upper end limit of the protective weight. 
The reviewed multi-country HPTN 024 trial showed that both weight extremes of low and high 
maternal weight are associated with PTD in HIV-infected women [36]. 
 
When ART became available, it had evident benefits of improved maternal health and reduced 
mother-to-child transmission of HIV infection. However, despite this advancement, a certain 
group of women still struggle to gain adequate weight during pregnancy, resulting in persistent 
adverse birth outcomes. For example, the PROMOTE-Pregnant Women and Infants trial in 
Uganda which randomised women to receive lopinavir/ritonavir versus efavirenz plus 
lamivudine/zidovudine found increased risk of PTD and LBW infants in women with 
inadequate weight gain during pregnancy; while women with high BMI at enrolment had 30% 
reduction in LBW infants (31, 35). However, the upper limit of the weight that was beneficial 
in the reduction of LBW was not indicated, as the highest category of BMI in this study was 
≥23 kg/m2. 
 
Two of the reviewed studies conducted in South Africa included clear sub-categories of high 
BMI (overweight, obese and morbidly obese) vs normal BMI, they found a maternal BMI-
dependent increase in the risk of PTD and macrosomic infants (32, 37). Although these 2 studies 
had HIV-infected groups, they did not report results according to HIV or ART status. A more 
recent finding that reported adverse birth outcomes by HIV status, found an increased risk of 
PTD and LBW in HIV-infected women, with women who are both HIV-infected and obese 
having higher risk of LBW compared to HIV-uninfected obese women (29). Low birth weight 
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infants in these women is thought to be due to obesity-related inflammation and oxidative stress 
exacerbated by HIV co-infection, resulting in endothelial dysfunction and compromised blood 
flow to the foetus (29, 72).  
 
Independent from HIV infection, ART has a detrimental impact on metabolic dysregulation 
which can greatly influence fetal growth. Regimens such as nucleoside reverse transcriptase 
inhibitors (NRTI’s) and protease inhibitors (PI’s) can sometimes increase the risk of 
lipodystrophy which is fat redistribution in the abdominal areas (73). In turn, lipodystrophy can 
further increase the risk of development of cardiovascular disease including diabetes mellitus, 
hyperlipaemia and pre-eclampsia (74). Consequently, these pregnancy complications have been 
implicated in mediating PTD, HBW and LGA infants. These adverse birth outcomes have long-
term effect on offspring’s health including neurodevelopmental delays and exposure to early 
childhood obesity and related morbidities (75). Since growing evidence suggests increased 
obesity prevalence in HIV-infected women that are using ART, incorporation of obesity 
prevention programs into routine HIV care is recommended to minimise adverse birth outcomes 
(29, 37, 76-78). 
 
5.4 Methodological Differences in the Literature 
The studies reviewed present different conclusions regarding the association between high BMI 
and adverse birth by HIV and ART status. These differences could be attributed to the different 
study populations, study designs and exposure groups as outlined below. 
 
5.4.1 Study Population  
The studies reviewed were conducted across 6 countries in SSA. These countries have different 
diets, HIV infection prevalence and background adverse birth outcomes due to other risks 
factors. Depending on the region in which the participants were recruited, women could have 
lower or higher prevalence of pre-pregnancy obesity. For example, in Rwanda it has been 
shown that obesity prevalence in women is higher in urban areas than in rural areas (79) which 
is common for any other country. Therefore, the findings of the study would be influenced by 
the proportion of obese women in the study which depends on the setting in which it was 
conducted as some studies recruited in rural and others in urban hospitals (24, 31). Besides in-
country differences, obesity prevalence ranges from a high of 68.5% in South African women 
to a low of 20% in Zambia (10). Therefore, it is plausible that Chaambwa (36) did not find any 
difference in obesity prevalence between HIV-infected and -uninfected women in Zambia 
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whereas Anderson et al. (29) found a higher prevalence of obesity in HIV-infected women in 
South Africa. Indeed, this result could also be attributed to the difference in HIV infection 
prevalence in these 2 countries.  
 
The timing of the study also affects the type of HIV-infected individuals that were included in 
the different studies. Studies that were conducted prior to 2002 used women who were not on 
treatment and hence could have been sicker and lost weight which influenced the adverse birth 
outcomes (23). Although the majority of studies conducted prior to 2010 also had untreated 
women, they may have been healthier with CD4 count >350 and were only given NVP regimen 
during delivery; as such, their outcomes would differ from those that had to be placed on 
HAART (22, 33, 36). Women on HAART have been shown to be at higher risk of adverse 
pregnancy outcome due to production of high levels of IL-10 rather than IL-2, favouring 
cytotoxic uterine environment and preterm labour (80). 
 
Other SSA countries are faced with anaemia and malaria as risks factors for adverse birth 
outcomes hence they included these factors in their investigations in addition to high BMI and 
HIV (33-35). Therefore, their findings would be different from those studies that do not have a 
concerning prevalence of these conditions in pregnant women. The studies also had participants 
with varying maternal ages of <20 – >40 years (33, 36). Old age increases the likelihood of 
multiparity and pregnancy complications which increases the risk of adverse birth outcomes 
(81) and this could attribute to differences observed in the studies reviewed.  
 
5.4.2 Study Designs and Exposure Groups 
Half of the studies reviewed were observational cohorts. In such studies there is a risk of 
misclassification due to measurement error of the exposure, which could lead to under or over 
estimation of the outcome. In addition, the exposed group tends to have other underlying risks 
factors for the outcome as risks factors cluster together. For example, Castetbon et al. (23) found 
that the HIV-infected participants had lower level of education compared to the uninfected 
group. This difference in demographics could be important in providing overestimated 
conclusions regarding adverse birth outcomes. Hence, if there is an imbalance in the distribution 
of risks factors among the comparison groups, the findings are normally unreliable. The 2 
retrospective cohorts on the other hand had a limitation of missing information that could have 
a significant impact on the findings (30, 37). Gadama (37) excluded about 380 women in the 
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analysis and was left with a sample size of 970 due to missing medical records and missing 
variables in some of the records that were found.  
 
In contrast, half of the studies reviewed were RCTs which have intense data collection that 
minimises missing information during the analysis. RCTs are characterised by randomisation 
of participants to 2 or more comparison groups. This randomisation reduces biased conclusions 
because it allows random distribution of known and unknown risks factors such that, if 
maintained, the differences that arise can be attributed to the intervention being studied. Hence, 
this type of design is regarded as being the best in providing reliable scientific evidence, 
provided they are planned, conducted, analysed, and reported appropriately as per research 
question (82). Unfortunately, in this case, all these trials were not primarily designed to study 
the exposure of interest hence their data may also be questionable. As a result, the obese groups 
were not clearly defined hence their findings are biased towards lower ends of maternal weight 
and adverse birth outcomes (31, 33-35). This led to a recommendation for interventions to 
improve maternal weight in these RCTs (33). However, there could have been a discrepancy 
regarding the association of maternal weight and adverse birth outcomes in these studies as they 
did not have an indication of overweight/obese groups in their population as their highest BMI 
category was >24.00 kg/m2 with no clear upper-end limit (23, 24, 31, 33-35). In contrast, most 
observational studies had standard weight categories (overweight, obese vs normal weight) and 
they found increased maternal weight to be associated with adverse infant outcomes and 
recommended weight reduction interventions in pregnant women (29, 36, 37). 
6. SUMMARY 
The studies reviewed show that available data do not reflect the trend of knowledge 
advancement regarding the relation of obesity and HIV infection. Most studies that investigated 
the association of BMI and adverse birth outcomes in HIV-infected populations were conducted 
in the era where HIV treatment was unavailable or only available during delivery. Therefore, 
they investigated maternal weight in the context of HIV-related weight loss rather than obesity; 
and hence concluded that low BMI is associated with adverse birth outcomes (23, 24, 31, 33-
35). Recent studies that included obese women in their study population report that high BMI 
is associated with adverse pregnancy outcomes (30, 32, 36, 37). However, these studies did not 
focus on HIV infection and ART-use in pregnancy despite the growing evidence of high obesity 
prevalence in these women (77, 78). Instead, they included HIV status due to the awareness 
that some study participants may have the infection, a known confounder for adverse birth 
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outcomes. The only study that was primarily designed to investigate both high BMI and HIV 
infection as risks factors for adverse birth outcomes was Anderson et al. (29). However, this 
study recruited women from a heavily polluted area because their intention was also to study 
ambient air pollution which has been reported to be a risk factor for adverse birth outcomes 
(83). Therefore, there is limited data regarding the association of high BMI and adverse birth 
outcomes by HIV and ART status in SSA. 
 
7. RECOMMENDATIONS 
Although there is a clear shift in the relation of HIV infection and maternal weight from weight 
loss to weight gain, research has not focused on studying these risks factors together. It is known 
that HIV infection is independently associated with maternal weight loss which in turn is related 
to adverse birth outcomes such as PTD, SGA and LBW. On the other hand, obesity has also 
been independently shown to be associated with both similar and opposite (macrosomia and 
LGA) adverse birth outcomes as HIV infection. Preterm delivery, SGA and LBW are associated 
with adverse health consequences including increased neonatal and infant mortality (84). Low-
income countries are particularly vulnerable to this problem as they lack resources for basic 
care for infections and breathing difficulties for these babies (45). Even in areas that have 
advanced medical care, infants that overcome poor birth outcomes face significant cognitive, 
behavioural, and developmental challenges in their childhood and throughout their lifetime (45, 
84, 85). Due to the evident benefit of HIV treatment on maternal and child health, there has 
been a dramatic increase in ART-use in HIV-infected pregnant women due to the WHO 
guidelines of UTT (86, 87). Consequently, recent data suggests that overweight and obesity 
prevalence is high in HIV-infected women using ART (77-79, 88-91). Therefore, research 
needs to establish whether the combined association between both obesity and HIV/ART-use 
in pregnancy and adverse birth outcomes exists.  
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Table 1a. Summary and key features of quality of included studies  
Study  Year  
published 
Country Time-period Setting Study population Sample 
size 
Study design Data collection  
Castetbon 
 
1999 Rwanda 
 
1992-1993 
 
Public hospital 
 
Pregnant women with GA ≤28 weeks 
 
371 
 
Prospective cohort 
 
Study measures 
 
Villamor 
 
2004 Tanzania 
 
1995-1997 
 
4 Maternity clinics 
 
Pregnant women with GA=12-27 weeks 
 
1002 
 
RCT Study measures 
 
Kruger 
 
2005 South Africa 
 
1 year (not 
mentioned) 
 
Maternity clinic 
 
Pregnant women booking for 1st ANC visit, 
with GA<28 weeks and singleton pregnancy 
 
91 Prospective cohort 
 
Study measures 
 
Banda 
 
2007 Zambia 
 
2000-2001 
 
2 Maternity clinics 
 
Pregnant women with GA ≥36 weeks OR at 
arrival in labour ward 
 
1211 
 
RCT Study measures     
Mehta 
 
2008 Tanzania, 
Zambia and 
Malawi 
 
2001-2003 
 
4 clinics; 1 in 
Zambia, 1 in 
Tanzania and 2 in 
Malawi, 
 
Pregnant women with GA = 20-24 weeks  
 
2126 
 
RCT Study measures 
 
Young 
 
2012 Uganda 
 
2009-2011 
 
Public hospital 
 
Pregnant women with GA = 12-28 weeks 
 
158 RCT Study measures 
 
Gadama 
 
2013 South Africa 
 
Jan - Apr 2011 
 
2 Maternity clinics 
 
Pregnant women booking for 1st ANC visit 
between Jan-Apr 2011 
 
970 
 
Retrospective 
cohort 
 
Data abstraction 
 
Koss 
 
2014 Uganda 2009-2012 
 
Public rural hospital 
 
Pregnant women booking for 1st ANC visit 
who are ART-naïve with GA 12-28 weeks  
 
356 
 
RCT Study measures 
 
van den Broek 
 
2014 Malawi 
 
n/a 3 Rural and 1 peri-
urban health centres  
 
Pregnant women with GA <24 weeks  
 
2149 
 
RCT 
 
Study measures 
 
Fouelifack 
 
2015 Cameroon 
 
Jan - Apr 2014 
 
Teaching hospital  
 
Women with singleton, term delivery 
between Jan - Apr 2014 
 
462 Retrospective 
cohort 
 
Study measures           
Data abstraction  
 
Chaambwa 
 
2016 Zambia 
 
2015-2016 
 
Teaching Hospital 
 
Pregnant women at term admitted in labour 
ward 
 
262 
 
Prospective cohort 
 
Study measures           
Data abstraction  
 
Anderson 
 
2018 South Africa 
 
2013-2014 
 
4 Maternity clinics  
 
Pregnant women in their 1st trimester  
 
437 Prospective cohort 
 
Study measures 
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Table 1b. Summary and key features of quality of included studies (exposures and outcomes) 
Study  Exposures (definition) Comparison groups Outcomes (definition) Outcomes 
assessment  BMI (kg/m2) GWG HIV/ART Preterm 
birth 
Birth weight Size for GA 
Castetbon 
 
Normal (25) vs high (>25) 
  
n/a HIV+ (Asymptomatic, elevated 
CD4 count, no treatment 
information) vs HIV- 
 
<37 weeks 
 
LBW: <2500g 
 
IUGR: LBW 
with GA ≥37 
weeks 
 
• Finnstrom score 
• Clinical 
examination 
(by study clinicians) 
Villamor 
 
Grouped by week of GA and 
categorised to quartiles 1-4 
 
• Regression slope ≤0 'Weight loss'; 
slope <25 'Low rate of weight gain' 
3 Types 
• Overall: Enrolment and Delivery 
• T2: GA week 12 and 26 
• T3: GA 27 and delivery  
 
HIV+ (untreated, 24% >stage 1; 
12% cd4<200/mm3) 
 
<37 weeks 
 
LBW: <2500g 
 
SGA: <10th 
percentile 
 
• LMP 
• Clinical 
examination 
(by study midwife)  
Kruger 
 
• Underweight: <19.8  
• Normal: 19.8 - ≤26.0 
• Overweight: >26.0 - <29.0 
• Obese:  ≥29.0" 
 
• Inadequate: < IOM recommend 
• Ideal: = IOM recommendation 
• Excessive: > IOM recommend 
 
HIV+ vs HIV- 
 
n/a Macrosomia: 
> 4000g 
 
n/a • US 
• Obstetric records 
Banda 
 
Quartiles 
• Q1: ≤22.7 
• Q2: >22.7 - ≤24.5 
• Q3: >24.5 - ≤26.8 
• Q4: >26.8 
 
n/a HIV+ (NVP regimen) vs HIV- 
 
n/a Mean birth 
weight 
 
n/a NR 
Mehta 
 
Tertiles 
• T1: <21.8 
• T2: 21.8 – 23.9 
• T3: ≥24.0 
 
• Weight Loss: <0 kg/wk 
• Low: 0.01-0.18 (≤25 percentile) 
• Normal: 0.19-0.41 (>25 - ≤75 
percentile) 
• High: ≥0.42 (>75 percentile) 
 
HIV+ (NVP at labour) 
 
<37 weeks 
 
LBW: <2500g 
 
 • SFH 
• Ballard 
Examination 
• LMP 
Young 
 
Tertiles 
• T1: <20.43 
• T2: 20.43-22.59 
• T3: >22.59 
 
<25th percentile (<0.1kg per week) 
vs ≥25th percentile (≥0.1kg per 
week) 
 
WHO stage1; ART-naïve 
(protease inhibitor or non-
nucleoside reverse transcriptase 
inhibitor-based ART regimen) 
 
<37 weeks 
 
LBW: <2500g 
 
SGA: <10th 
percentile 
 
• LMP 
• US 
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Study  Exposures (definition) Outcomes (definition) Outcomes 
assessment  BMI (kg/m2) GWG HIV/ART Preterm delivery Birth weight Size for GA 
Gadama 
 
• Normal: 18.5 - 24.9 
• Overweight: 25.0 - 29.9 
• Obese: 30.0-39.9                               
• Morbidly Obese: ≥40.0 
 
n/a HIV+ and HIV- 
 
n/d • Macrosomia: ≥ 
4000g 
 
n/a Obstetric records 
 
Koss 
 
• <20 
• 20 <23 
• ≥23 
 
• <0.1 kg/week 
• ≥0.1 kg/week 
 
ART-naïve: lopinavir/ritonavir 
versus efavirenz PLUS 
lamivudine/zidovudine in both 
arms 
 
• Very preterm: <32 
weeks                               
• Preterm: <37 weeks    
 
n/a n/a • LMP if concordant 
with US GA 
• US if LMP and US 
discordant 
 
van den 
Broek 
 
• Underweight: <18.5  
• Normal: > 18.5 
 
• Weight gain: n/d 
• Weight loss: n/d 
 
HIV+ (untreated, only given at 
delivery) and HIV- 
 
• Overall: <37 weeks 
• Early: 24-33 weeks 
• Late: 34-36 weeks 
 
n/a n/a US 
Fouelifack 
 
• Underweight: <18.5  
• Normal: 18.5 - ≤24.9 
• Overweight: 25.0 - ≤29.9 
• Obese:  ≥30.0 
 
• < IOM recommendation 
•  = IOM recommendation 
• > IOM recommendation 
 
HIV+ and HIV- 
 
n/a •  LBW: <2500g                     
•  Macrosomia: ≥ 
4000g 
 
n/a Obstetric records 
Chaambwa 
 
• Normal: 18.5-25.0  
• Obese: >30 
 
n/a HIV+ (5.3% not on treatment; 
17.6% on HAART) vs HIV- 
 
n/a Mean birth  
weight 
n/a Obstetric records 
Anderson 
 
• Non-obese: <30  
• Obese: > 30 
 
n/a HIV+ vs HIV- 
 
• Term: >37 weeks  
• Pre-term: <37 
weeks 
 
•  NBW: >2500g  
•  LBW: <2500g 
 
n/a NR 
 
*n/a – not assessed 
*n/d – not defined 
*NR – not recorded 
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Table 2. Key findings from included studies  
Study   Key Finding 
Castetbon 
 
• Mean weight lower for HIV+ at enrolment (59.4kg vs 62.2kg); and at last ANC visit (61.3kg vs 64.1kg); due to infection not SES 
• LBW higher in HIV+ (18.6% vs 9.3%) 
• Low maternal weight at last visit associated with LBW (OR 0.94, 95% CI 0.89-0.99) 
• LBW mechanism: HIV infection à intestinal malabsorption and metabolic disturbance à reduced maternal weight àreduce nutrient to foetus àLBW infant 
• Preterm births higher in HIV+ (21.5% vs 11.9%) 
• IUGR higher in HIV+ (6.8% vs 2.6%) 
 
Villamor 
 
• Prevalence of pregnancy loss = 8%, preterm birth = 25%, LBW =11% and SGA = 11% 
• Baseline Q4 weight (231g, 95% CI 132-330) and Q4 BMI (180g, 95% CI 90-271) associated with increased birth weight  
• Baseline Q4 weight (RR 0.47, 95% CI 0.24-0.94) and Q4 BMI (RR 0.40, 95% CI 0.23-0.70) associated with reduced risk of SGA  
• Weight loss (RR 1.85, 95% CI 1.40-2.44) and low weight gain (RR 1.34, 95% CI 1.34) associated with preterm delivery  
 
Kruger 
 
• Women with higher pre-pregnancy BMI gained excessive weight during pregnancy                                                                                                                                   
• Overweight/obese women had more macrosomic babies (9.7% vs 1.6% normal weight) 
 
Banda 
 
• Unit increase in BMI increases infant birth weight to a lesser extent (but not significant) in HIV-infected women (28.3g, 95% CI 14.0-42.6) vs HIV uninfected (32.7g, 95% 
CI 23.5-41.9) 
 
Mehta 
 
• T1  BMI (vs T3) is associated with preterm births (OR 1.82, 95% CI 1.34-2.46) and LBW (OR 2.09, 95% CI 1.41-3.08) 
• Weight loss (vs normal weight) is associated with preterm births (OR 2.16, 95% CI 1.55-3.00) 
• High weight gain (vs normal weight) is associated with preterm births (OR 1.55, 95% CI 1.14-2.12) 
• Weight loss (vs normal weight) is associated with LBW (OR 2.30, 95% CI 1.52-3.47) 
 
Young 
 
• Prevalence of LBW =19.6%, preterm delivery = 17.7% and SGA =15.5%  
• Increased maternal weight associated with 30% reduced risk of LBW (OR 0.70, 95% CI 0.52-0.95)                                                                                                          
• Low weight gain associated with LBW (OR 6.18, 95% CI 1.80-21.1)                                                                                                                                              
• Low weight gain associated with preterm birth (OR 3.46, 95% CI 1.18-10.15) 
 
Gadama 
 
• In HIV-infected group, there were more women in the obese category than normal weight                                                                                                            
• Risk of having macrosomic babies increased with increasing maternal BMI; overweight (OR 1.69, 95% CI 0.76-3.77), obese (OR 4.71, 95% CI 2.45-9.06), morbidly obese 
(OR 9.2, 95% CI 4.61-18.55) compared to normal weight                                                                                                                                                 
• Risk of preterm deliveries increased with increasing maternal BMI; obese (OR 1.10, 95% CI 0.68-1.95), morbidly obese (OR 2.26, 95% CI 1.20-4.15) 
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Study   Key Finding 
Koss 
 
• There was no difference in risk of preterm and very preterm births between the 2 ART arms (OR = 1.12, 95% CI 0.63–2.00)                                                                               
• Women who gained less than 0.1 kg/week versus 0.1 kg or more per week had higher odds of preterm birth (OR = 2.49, 95% CI 1.38–4.47) 
 
van den Broek 
 
• Greater proportion of women with preterm births (vs term) had underweight BMI (9.3% vs 3.2%)                                                                                                 
• Women with preterm births (vs term) gained less weight between 1st and 3rd trimester (2.94 vs 3.39)                                                                                            
• Increasing BMI (OR = 0.91, 95% CI 0.85-0.97) and weight gain (OR = 0.89, 95% CI 0.82-0.97) are associated with reduced odds of preterm births 
 
Fouelifack 
 
• Prevalence of LBW =11% and macrosomia= 7%                                                                                                                                                                              
• No significant association between BMI/GWG with LBW and macrosomia 
 
Chaambwa 
 
• There were no differences in BMI between HIV+ and HIV- mothers                                                                                                                                                       
• Obesity is associated with increased birth weight (OR 3.60, 95% CI 2.05-6.32) than normal weight women 
 
Anderson 
 
• High prevalence of obesity in HIV+ women (45.3% vs 27.4% non-obese)                                                                                                                                      
• HIV+ women had higher risk of having LBW infant (14.67% vs 10.09% HIV-)                                                                                                                             
• HIV+ women had higher risk of having preterm birth (18.67% vs 8.26% HIV-)                                                                                                                              
• Being obese and HIV+ increased risk of having a LBW (28.99% vs 5.38% non-obese)                                                                                                                   
• LBW mechanism: compromised blood flow to the foetus due to inflammation, oxidative stress, endothelial dysfunction and atherosclerosis caused by obesity and HIV 
infection 
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ABSTRACT 
Objectives: To examine the association of high BMI (overweight and obese) and gestational 
weight gain (GWG) with adverse birth outcomes by HIV and ART status in women seeking 
antenatal care. 
 
Design: Observational prospective cohort study. 
 
Setting: Recruitment took place in a maternity obstetric unit (MOU) at a primary healthcare 
facility located in a peri-urban area in Cape Town. 
 
Participants: A total of 3254 HIV-infected and HIV-uninfected black women seeking 
antenatal care at Gugulethu MOU was enrolled. A subset of 549 HIV-infected women who 
booked early (≤24weeks) was prospectively followed through delivery.  
 
Primary and Secondary Outcome Measures: The adverse birth outcomes of interest were 
preterm delivery (PTD), low/high birthweight (LBW/HBW) and small/large gestational age 
(SGA/LGA) infants.  
 
Results: There was no association (aOR 1.06, 95% CI 0.75-1.49) between obese BMI and PTD, 
regardless of HIV and ART status compared to normal BMI. However, obese BMI was 
negatively associated with LBW (aOR 0.53, 95% CI 0.39-0.72) and SGA (aOR 0.55, 95% CI 
0.41-0.75) compared to normal BMI. Inversely, obese BMI was positively associated with 
HBW (aOR 2.00, 95% CI 1.13-3.57) and LGA (aOR 1.98, 95% CI 1.40-2.80) regardless of 
HIV and ART status compared to normal BMI. Restricting the analysis to obese HIV-infected 
women only, revealed a counter effect of the two conditions where the frequencies of both LGA 
and SGA are high. Although the association of high GWG and adverse birth outcomes showed 
similar trends as obese BMI, statistical significance was not consistently obtained.  
 
Conclusions: Obese HIV-infected women appear to be cushioned by their BMI against LBW 
and SGA when compared to normal BMI. However, comparison of these outcomes amongst 
women who are either obese or HIV-infected reveal a higher burden of both SGA and LGA 
infants in obese HIV-infected women, regardless of ART initiation status. 
 
 
 
 
4 
 
Strengths and Limitations of this Study 
• Large sample size, enabled detection of differences between groups. 
• Comparison of adverse birth outcomes in multiple groups of women: obese only, HIV-
infected only and obese HIV-infected women who initiated ART before and during 
pregnancy. 
• Use of IOM guidelines for GWG may not be applicable to African Black women. 
• Small sample size for the subset of women studied for GWG. 
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1. INTRODUCTION 
Obesity has previously been regarded as the disease of the rich that is highly prevalent in 
Western countries. However, recent evidence shows a constant rise in obesity in low-income 
countries (1, 2). South Africa is the most obese region in Sub-Sahara, with women of child-
bearing age carrying the most burden of approximately 70% (3, 4). Consequently, the South 
African Department of Health recently declared obesity driven non-communicable diseases 
(NCD) as being amongst the top 10 leading causes of mortality and morbidity (3). Overweight 
and obese women are likely to gain more weight during pregnancy and to retain the weight after 
delivery (5). Therefore, women from SSA countries are at high risk of accumulating weight due 
to frequent and short-term interval pregnancies; in addition to excess consumption of high 
fat/sugar diets. 
Foetal development is dependent on maternal nutrition status which ultimately determines 
obstetric and neonatal outcomes (6). Consequently, infants born from women with pre-
pregnancy obesity or excessive gestational weight gain have increased risk of adverse health 
outcomes. The adverse birth outcomes related to high BMI (overweight and obese) include 
macrosomic (birth weight ≥4kg) and LGA (>90th percentile) infants (7, 8). This is supported by 
longitudinal data showing an increase in mean infant birth weight paralleled by increased mean 
maternal weight at first antenatal care booking (9-11).  
 
Big babies are at greater risk of congenital anomalies, low Apgar score, asphyxia and perinatal 
or neonatal death (12, 13). Those that survive these poor outcomes are likely to experience 
childhood obesity and the associated cardiovascular and metabolic complications which lead to 
premature mortality (14-17). In contrast, other studies report that high BMI is associated with 
LBW (<2500g), SGA (<10th percentile) and PTD (<37 weeks) (18-22). Preterm and LBW are 
amongst the leading causes of neonatal and under-5 years child mortality (23). Low-income 
countries are particularly vulnerable to these adverse outcomes as they lack resources for basic 
care for infections and breathing difficulties for these babies (24, 25). On the other hand, infants 
that do overcome these poor birth outcomes face significant cognitive, behavioural and 
developmental challenges in their childhood and throughout their lifetime (23, 24, 26). 
 
Adding complexity to the association between high BMI and adverse birth outcomes is HIV 
infection which mostly affects the same population group of women of child-bearing age. 
Despite the ART program being one of the greatest successes in public health interventions, 
strong evidence from HIV prevalent countries suggests that HIV infection and/or ART-use in 
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pregnancy are associated with LBW, SGA and PTD (27-31). The established independent 
association of obesity and HIV/ART with adverse birth outcomes is due to vast research which 
has focused on studying these exposures separately. As a result, there is limited literature on 
the combined impact between the double burden of obesity and HIV and adverse birth 
outcomes. Therefore, we examined the association between high pregnancy BMI and adverse 
birth outcomes by HIV and ART status in women seeking ANC in Cape Town, South Africa.  
 
2. METHODS 
2.1 Study Design 
This study was a secondary data analysis of a large observational cohort that investigated 
Prematurity Immunology in Mothers and their Infants (PIMS study).  
 
2.2 Study Setting 
Study participants were recruited at Gugulethu MOU. Gugulethu is a semi-urban area with a 
population of 98 468, predominantly made up of 98.8% black African ethnic group with low 
socioeconomic status (32, 33). The MOU provides antenatal, obstetric and infant care for 
approximately 5 000 women (per annum) with low risk pregnancies, who deliver with the help 
of midwives. Women with previous history of pregnancy complications and first ANC bookers 
who are considered as high-risk pregnancies are referred to secondary and tertiary health care 
facilities.  
 
2.3 Inclusion and Exclusion Criteria 
This analysis included HIV-uninfected and HIV-infected women aged ≥18 years, with 
singleton pregnancy, booking for their first ANC between April 2015 and October 2016 in 
Gugulethu MOU. Pregnant women with multiple pregnancies, underweight BMI (<18.5) and 
gestational weight loss were excluded from the analysis since these are potential confounders 
of adverse birth outcomes (Figure 1). Specifically, the population of interest for this study are 
women who have normal, overweight and obese BMI and women who gained weight during 
pregnancy. Women with missing weight/height measurements and total gestational weight gain 
were also excluded. 
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Figure 1. Flow diagram showing the selection of women included in the analysis  
 
2.4 Study Procedures and Data Collection 
The parent study was reviewed and approved by the University of Cape Town Faculty of Health 
Sciences Research Ethics Committee (UCT-HREC) (739/2014) (Appendix 2B) and the 
University of Southampton Institutional Review Board (12542 PIMS) (Appendix 2C). Written 
informed consent for data collection using study questionnaires and abstraction of medical 
record data was obtained from all participants (Appendix 3A and 3B). Ethical approval for the 
current study was obtained from the UCT-HREC (350/2018) (Appendix 2A) and no further 
informed consent was required from the study participants. 
 
Exposure measurements: weight and height measurements for BMI calculation were performed 
by health practitioners as part of routine ANC and abstracted into the study abstraction form 
(Appendix 4B). BMI was categorised into normal (18.5-24.9), overweight (25-29.9) and obese 
(≥30) in kg/m2 categories by HIV and ART status (Assessment A). Gestational weight gain 
assessment was only performed in the subset of HIV-infected women that booked early (≤24 
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weeks) as they had follow-up study visits and weight measurements collected by trained study 
personnel (Assessment B). Total weight gain was calculated as the difference between weight 
at last study visit before delivery and first ANC visit; and was categorised as low, adequate and 
high weight gain in relation to the IOM guidelines (34, 35). 
 
Outcome assessment: gestational age at booking is routinely measured by health practitioners 
using last menstrual period and symphysis-fundal height (SFH). As part of study procedures, 
some participants had their GA assessed by ultrasonography operated by an experienced 
sonographer. This booking GA and date of delivery obtained from clinic records were used to 
calculate gestation at delivery. Delivery GA was categorised into term (≤37) and preterm (<37) 
deliveries in weeks. Infant birth weight and sex were obtained from data abstracted from 
medical records. Infant birth weight was categorised into low (<2500), normal (2500 – 3999) 
and high (≥4000) birthweight in g. Size for gestational age was obtained based on infant 
gestational age, birthweight and sex using INTERGROWTH-21st Project tool; and was 
categorised into small (<10th), appropriate (10-90th) and large (>90th) gestational age in 
percentiles (36).   
 
Additional information regarding demographics, medical history and obstetric was obtained 
from medical records and from questionnaires completed at various study follow-up visits for 
the subset of HIV-infected women that was followed through to 12 months post-partum. 
 
2.5 Data Analysis 
All data was analysed using STATA (version 14.0, Stata Corporation, College Station, TX, 
USA). Numerical continuous variables are presented as mean (SD) and/or medians (IQR). 
Categorical variables are presented as counts and proportions, Chi-Squared test was used for 
comparison between groups. The analysis focused on the exposures: 
i) BMI only (normal, overweight and obese) 
ii) BMI and HIV status (HIV-uninfected vs HIV-infected) 
iii) BMI and ART status (ART initiation before pregnancy and ART initiation during 
pregnancy) and; 
iv) GWG (low, adequate and high) 
The association between exposures and birth outcomes (PTD, LBW, HBW, SGA and LGA) 
was tested using logistic regression; and results are presented as adjusted odds ratios (aOR) 
with 95% confidence intervals (CI). All models were adjusted for a priori confounders such as 
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maternal age, gestation at enrolment, parity and previous PTD (37). Differences between groups 
were considered statistically significant at p<0.05. 
 
3. RESULTS  
3.1 Assessment A 
A total of 2779 women with live singleton births were included in this analysis: 556 normal 
BMI (20%), 807 overweight (29%) and 1416 obese (51%). In total, 1699 were HIV-uninfected 
(61%) and 1080 HIV-infected (39%), of which 539 (50%) initiated ART before pregnancy and 
541 (50%) during pregnancy (Figure 1). Obese BMI prevalence was similar between HIV-
uninfected (51%) and -infected women (50%). Obese HIV-infected women were more likely 
to be older, book early for ANC, have higher gravid and parity compared to obese HIV-
uninfected women (Table 1).  
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Table 1. Maternal baseline characteristics of enrolled participants with live singleton births by 
BMI and HIV status (n = 2779). 
 
*p-value less than 0.05  
#Amongst women with a previous pregnancy
  HIV-uninfected  
n = 1699 
 HIV-infected  
n = 1080           
 
  
Total 
n = 2779  
BMI  
Chi2 
p-value  
BMI  
Chi2 
p-value Normal  n = 336 
Overweight 
n = 492 
Obese 
n = 871 
Normal  
n = 220 
Overweight 
n = 315 
Obese 
n = 545 
Age (years)     <0.001*    <0.001* 
<20 273 (10) 86 (26) 81 (16) 53 (6)  16 (7) 18 (6) 19 (3)  
20-24 604 (22) 112 (33) 150 (30) 187 (21)  46 (21) 46 (15) 63 (12)  
25-29 786 (28) 81 (24) 143 (29) 258 (30)  69 (31) 84 (27) 151 (28)  
30-34 700 (25) 44 (13) 86 (17) 213 (24)  69 (31) 105 (33) 183 (34)  
≥35 416 (15) 13 (4) 32 (7) 160 (18)  20 (9) 62 (20) 129 (24)  
Median (IQR) 28 (23-32) 23 (20-27) 25 (22-29) 28 (24-33)  28 (24-32) 30 (25-34) 31 (26-34)  
          
Height (cm)      0.517    0.490 
≤155 939 (34) 103 (31) 160 (33) 290 (33)  74 (34) 103 (33) 209 (38)  
156-161 1053 (38) 138 (41) 182 (37) 349 (40)  79 (36) 118 (37) 187 (34)  
≥162 787 (28) 95 (28) 150 (30) 232 (27)  67 (30) 94 (30) 149 (27)  
Median (IQR) 158  
(154-162) 
158  
(155-162) 
158  
(154-162) 
158  
(154-162) 
 159  
(154-163) 
158  
(154-163) 
157  
(154-162) 
 
          
Obstetrics          
GA (weeks)     0.006*    0.195 
1st trimester (≤13) 712 (26) 84 (25) 100 (20) 197 (23)  72 (33) 87 (28) 172 (32)  
2nd trimester (14-28) 1598 (58) 212 (63) 298 (61) 510 (59)  118 (54) 171 (54) 289 (53)  
3rd trimester (>28) 406 (15) 32 (10) 78 (16) 152 (17)  21 (10) 51 (16) 72 (13)  
Median (IQR) 19 (13-25) 18 (13-23) 20 (14-27) 20 (14-26)  17 (12-21) 19 (13-26) 18 (12-24)  
Missing  63 (2) 8 (2) 16 (3) 12 (1)  9 (4) 6 (2) 12 (2)  
          
Gravidity      <0.001*    <0.001* 
1 673 (24) 151 (45) 164 (33) 177 (20)  51 (23) 62 (20) 68 (12)  
2 951 (34) 108 (32) 179 (36) 289 (33)  89 (40) 102 (32) 184 (34)  
≥3 1148 (41) 77 (23) 149 (30) 404 (46)  78 (35) 149 (47) 291 (53)  
Median (IQR) 2 (2-3) 2 (1-2) 2 (1-3) 2 (2-3)  2 (2-3) 2 (2-3) 3 (2-3)  
Missing  7 (0.3) 0 0 1 (0.1)  2 (1) 2 (0.6) 2 (0.4)   
          
Parity     <0.001*    <0.001*  
0 822 (30) 183 (54) 192 (39) 205 (24)  69 (31) 82 (26) 91 (17)  
1 1038 (37) 100 (30) 185 (38) 326 (37)  94 (43) 106 (34) 227 (42)  
≥2 911 (33) 53 (16) 115 (23) 339 (39)  55 (25) 125 (40) 224 (41)  
Median (IQR) 1 (0-2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        0 (0-1) 1 (0-1) 1 (1-2)  1 (0-2) 1 (0-2) 1 (1-2)  
Missing 8 (0.3) 0 0 1 (0.1)  2 (1) 2 (0.6) 3 (0.5)  
          
Prior preterm#     <0.001*    0.017* 
Yes 200 (7) 15 (4) 27 (5) 64 (7)  21 (10) 30 (10) 43 (8)  
          
Prior pregnancy 
loss# 
    <0.001*    0.115 
Yes  333 (12) 40 (12) 40 (8) 90 (10)  35 (16) 41 (13) 87 (16)  
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Preterm Delivery 
The total estimated incidence of PTD was 18% and was slightly higher in HIV-infected women 
with normal BMI (22%) compared to those with obese BMI (19%) (Table 2). However, 
comparison of obese HIV-uninfected and obese HIV-infected women showed a slightly higher 
PTD incidence (16% vs 19%) in obese HIV-infected women. Overall, adjusted results showed 
a positive but non-significant association between obese BMI and PTD (aOR 1.06, 95% CI 
0.75-1.49) compared to normal BMI (Supplement Table 4) (Appendix 1). When stratifying the 
analysis by HIV status, adjusted logistic regression results also showed that there was no 
association between obese BMI and PTD in obese HIV-uninfected women (aOR 1.08, 95% CI 
0.66-1.77) and obese HIV-infected participants (aOR 1.02, 95% CI 0.63-1.64) when compared 
to corresponding women with normal BMI (Table 3). Similarly, restricting the analysis to HIV-
infected women by timing of ART initiation also showed no association between PTD and 
obese BMI and HIV infection in those who initiated ART during (aOR 1.03, 95% CI 0.50-2.11) 
and before (aOR 1.01, 95% CI 0.53-1.93) pregnancy when compared to corresponding women 
with normal BMI (Supplement Table 5) (Appendix 1). 
 
Birth Weight 
Low Birth Weight: The total estimated incidence of LBW was 12% with obese women having 
a significantly lower incidence (10%) compared to normal BMI (17%) women (Supplement 
Table 2). Stratifying by HIV infection also showed a lower LBW incidence in obese compared 
to normal BMI in HIV-uninfected (8% vs 13%) and HIV-infected (12% vs 21%) women (Table 
2). However, between group comparison of obese HIV-uninfected and obese HIV-infected 
women showed a slightly higher LBW incidence (12% vs 8%) in obese HIV-infected women 
(Table 2). Restricting the analysis to HIV-infected women by timing of ART initiation and BMI 
status showed a slightly lower LBW incidence (11% vs 14%) in obese women who initiated 
ART during pregnancy when compared to corresponding normal BMI women (Supplement 
Table 3).   
 
Overall adjusted results showed a significant negative association between obese BMI and 
LBW (aOR 0.53, 95% CI 0.39-0.72) compared to normal BMI (Supplement Table 4) (Appendix 
1). When stratifying the analysis by HIV status, adjusted logistic regression results also showed 
a significant negative association between obese BMI and LBW in obese HIV-uninfected 
women (aOR 0.51, 95% CI 0.34-0.78) and obese HIV-infected participants (aOR 0.54, 95% CI 
0.35-0.83) when compared to corresponding normal BMI women (Table 3). Similarly, 
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restricting the analysis to HIV-infected women by timing of ART initiation also showed a 
significant negative association between obese BMI and HIV infection and LBW in those who 
initiated ART during (aOR 0.51, 95% CI 0.27-0.94) but not statistically significant for those 
that initiated ART before (aOR 0.56, 95% CI 0.30-1.04) pregnancy when compared to 
corresponding normal BMI women (Supplement Table 5).   
 
High Birth Weight: The total estimated incidence of HBW is 5% with obese women having a 
significantly higher incidence (6%) compared to normal BMI (3%) women (Supplement Table 
2). Stratifying by HIV infection also showed a higher HBW incidence in obese compared to 
normal BMI in HIV-uninfected (7% vs 3%) and HIV-infected (5% vs 3%) women compared 
to corresponding women with normal BMI (Table 2). However, between group comparison of 
obese HIV-uninfected and obese HIV-infected women showed a slightly lower HBW incidence 
(7% vs 5%) in obese HIV-infected women (Table 2). Restricting the analysis to HIV-infected 
women by timing of ART initiation and BMI status showed a higher HBW incidence (7% vs 
3%) in obese women who initiated ART during pregnancy when compared to corresponding 
normal BMI women (Supplement Table 3).  
 
Overall adjusted results showed a significant positive association between obese BMI and 
HBW (aOR 2.00, 95% CI 1.13-3.57) compared to normal BMI (Supplement Table 4) 
(Appendix 1). When stratifying the analysis by HIV status, adjusted logistic regression results 
also showed a significant positive association between obese BMI and HBW in obese HIV-
uninfected women (aOR 2.54, 95% CI 1.17-5.53) and a positive but non-significant association 
in obese HIV-infected participants (aOR 1.41, 95% CI 0.59-3.34) when compared to 
corresponding normal BMI women (Table 3). Restricting the analysis to HIV-infected women 
by timing of ART initiation showed a positive but non-significant association between obese 
BMI and HIV infection and HBW in those who initiated ART during pregnancy (aOR 2.10, 
95% CI 0.68-6.48) and a reversed effect in those who initiated ART before (aOR 0.71, 95% CI 
0.18-2.83) pregnancy when compared to corresponding normal BMI women (Supplement 
Table 5).   
 
Size for Gestational Age 
Small for Gestational Age: The total estimated incidence of SGA is 12% with obese women 
having a significantly lower incidence (10%) compared to normal BMI (16%) women 
(Supplement Table 2). Stratifying by HIV infection also showed a lower SGA incidence in 
obese compared to normal BMI in HIV-uninfected (8% vs 15%) and HIV-infected (12% vs 
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18%) women (Table 2). However, between group comparison of obese HIV-uninfected and 
obese HIV-infected women showed a slightly higher SGA incidence (8% vs 12%) in obese 
HIV-infected women (Table 2). Restricting the analysis to HIV-infected women by timing of 
ART initiation and BMI status showed a slightly lower SGA incidence (10% vs 14%) in obese 
women who initiated ART during pregnancy (Supplement Table 3). 
 
Overall adjusted results showed a significant negative association between obese BMI and SGA 
(aOR 0.55, 95% CI 0.41-0.75) compared to normal BMI (Supplement Table 4) (Appendix 1). 
When stratifying the analysis by HIV status, adjusted logistic regression results also showed a 
significant negative association between obese BMI and SGA in obese HIV-uninfected women 
(aOR 0.51, 95% CI 0.34-0.78) and in obese HIV-infected participants (aOR 0.60, 95% CI 0.38-
0.94) when compared to corresponding normal BMI women (Table 3). Restricting the analysis 
to HIV-infected women by timing of ART initiation showed a negative but non-significant 
association between obese BMI and HIV infection and SGA in those who initiated ART during 
pregnancy (aOR 0.65, 95% CI 0.34-1.26) and a significant negative association in those who 
initiated ART before (aOR 0.53, 95% CI 0.29-0.99) pregnancy when compared to 
corresponding normal BMI women (Supplement Table 5).  
 
Large for Gestational Age: The total estimated incidence of LGA is 13% with obese women 
having a significantly higher incidence (17%) compared to normal BMI (8%) women 
(Supplement Table 2). Stratifying by HIV infection also showed a higher LGA incidence in 
obese compared to normal BMI in HIV-uninfected (18% vs 8%) and HIV-infected (14% vs 
9%) women (Table 2). However, between group comparison of obese HIV-uninfected and 
obese HIV-infected women showed a slightly lower LGA incidence (18% vs 14%) in obese 
HIV-infected women (Table 2). Restricting the analysis to HIV-infected women by timing of 
ART initiation and BMI status showed a similar LGA incidence (15% vs 14%) in obese women 
who initiated ART during and before pregnancy when compared to corresponding normal BMI 
women (Supplement Table 3). 
 
Overall adjusted results showed a significant positive association between obese BMI and LGA 
(aOR 1.98, 95% CI 1.40-2.80) compared to normal BMI (Supplement Table 4) (Appendix 1). 
When stratifying the analysis by HIV status, adjusted logistic regression results also showed a 
significant positive association between obese BMI and LGA in obese HIV-uninfected women 
(aOR 2.30, 95% CI 1.46-3.62) and a positive but non-significant association in obese HIV-
infected participants (aOR 1.58, 95% CI 0.91-2.72) when compared to corresponding normal 
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BMI women (Table 3). Restricting the analysis to HIV-infected women by timing of ART 
initiation showed a significant positive association between obese BMI and HIV infection and 
LGA in those who initiated ART during pregnancy (aOR 3.26, 95% CI 1.32-8.09) and a 
reversed effect in those who initiated ART before (aOR 0.87, 95% CI 0.43-1.78) pregnancy 
when compared to corresponding normal BMI women (Supplement Table 5).   
Focusing the analysis on the frequencies of SGA and LGA infants provided the summary of 
the findings shown in Figure 2. Women who are obese only have lower SGA frequency than 
LGA (Figure 2A), whereas women who are HIV-infected only have the opposite i.e higher 
SGA than LGA (Figure 2B) when compared to corresponding normal BMI women. Thereby, 
resulting in obese HIV-infected women to experience a counter effect of both obese BMI and 
HIV/ART where SGA and LGA frequencies are both high compared to those who have one of 
the conditions, regardless of ART initiation status (Figure 2C and D). 
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Table 2. Incidence of adverse birth outcomes by BMI and HIV status among women with live singleton births (n = 2779) 
 
 
 
*p-value less than 0.05  
 
 
 
 
 HIV-uninfected  
n = 1699 
 HIV-infected  
n = 1080           
 
 BMI  
Chi2 
p-value  
BMI  
Chi2 
p-value 
Normal  
n = 336 
Overweight 
n = 492 
Obese 
n = 871 
Normal  
n = 220 
Overweight 
n = 315 
Obese 
n = 545 
GA (weeks)    0.173    0.321 
Preterm (<37) 56 (17) 89 (18) 143 (16)  49 (22) 52 (17) 105 (19)  
Term (≥37) 272 (81) 387 (79) 716 (82)  167 (76) 259 (82) 436 (80)  
Missing 8 (2) 16 (3) 12 (1)  4 (2) 4 (1) 4 (0.7)  
         
Birth weight (g)    0.001*    0.005* 
Low (<2500) 45 (13) 58 (12) 71 (8)  47 (21) 34 (11) 75 (12)  
Normal (2500 - 3999) 281 (84) 417 (85) 743 (85)  165 (75) 269 (85) 448 (82)  
High (≥4000) 9 (3) 17 (3) 57 (7)  7 (3) 8 (2.5) 27 (5)  
Mean (SD) 3049 (543) 3115 (590) 3256 (555)  2891 (623) 3081 (531) 3126 (591)  
Missing 1 (0.3) 0 0  1 (0.5) 4 (1) 4 (0.7)  
         
Size for GA    <0.001*    0.024* 
Small (<10th) 50 (15) 59 (12) 70 (8)  40 (18) 59 (19) 65 (12)  
Appropriate (10-90th) 237 (71) 333 (68) 598 (69)  153 (70) 216 (69) 381 (70)  
Large (>90th) 27 (8) 61 (12) 159 (18)  19 (9) 28 (9) 77 (14)  
Missing 22 (7) 39 (8) 44 (5)  8 (4) 12 (4) 22 (4)  
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Table 3. Adjusted odds of adverse birth outcomes by HIV status among women with high BMI compared to normal BMI (n = 2779). 
 
*p-value less than 0.05  
aOR – Odds ratio 
Preterm model – logistic regression: adjusted for maternal age, GA at enrolment, parity, prior PTD, ART status 
Birth weight model – multinomial logistic regression: adjusted for maternal age, GA at enrolment, parity, ART status 
Size for GA model – multinomial logistic regression: adjusted for maternal age, GA at enrolment, parity, ART status 
 
 
 
 
 
 
 HIV-uninfected  
n = 1699 
HIV-infected  
n = 1080       
 BMI BMI 
Overweight 
n = 492 
Obese 
n = 871 
Overweight 
n = 315 
Obese 
n = 545 
 aOR (95% CI) p-value aOR (95% CI) p-value aOR (95% CI) p-value aOR (95% CI) p-value 
GA (weeks)         
Preterm (<37) 0.88 (0.52-1.50) 0.641 1.08 (0.66-1.77) 0.762 1.26 (0.74-2.17) 0.394 1.02 (0.63-1.64) 0.942 
         
Birth weight (g)         
Low (<2500) 0.82 (0.53-1.25) 0.358 0.51 (0.34-0.78) 0.002* 0.46 (0.28-0.76) 0.002* 0.54 (0.35-0.83) 0.005* 
High (≥4000) 1.35 (0.57-3.21) 0.501 2.54 (1.17-5.53) 0.019* 0.70 (0.25-2.00) 0.508 1.41 (0.59-3.34) 0.440 
         
Size for GA         
Small (<10th) 0.81 (0.54-1.24) 0.336 0.51 (0.34-0.78) 0.002* 0.92 (0.58-1.46) 0.721 0.60 (0.38-0.94) 0.026* 
Large (>90th) 1.55 (0.95-2.53) 0.077 2.30 (1.46-3.62) <0.001* 1.01 (0.54-1.88) 0.987 1.58 (0.91-2.72) 0.103 
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Figure 2. Comparison of frequencies of SGA and LGA infants within groups: women who are obese only (A), HIV-infected only (B), obese 
HIV-infected with ART initiation during pregnancy (C) and obese HIV-infected with ART initiation before pregnancy (D). 
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3.2 Assessment B 
A total of 364 HIV-infected women with live singleton births were included. Obese HIV-
infected women were more likely to be older, not complete high school, have higher gravidity, 
parity and previous pregnancy losses compared to normal BMI women (Supplement Table 6). 
Although most women gained lower weight than recommended by IOM, obese women gained 
higher than recommended compared to normal BMI women (19% vs 4%) (Supplement Table 
7). Adjusted logistic regression results showed a positive but non-significant association 
between low GWG and PTD (aOR 1.37, 95% CI 0.39-4.82) and negative but non-significant 
association with high GWG (aOR 0.45, 95% CI 0.09-2.24) compared to adequate GWG (Table 
4).  
 
With regards to birth weight, women with low GWG had a higher incidence of LBW (12%) 
compared to those with adequate (8%) and high GWG (7%) (Supplement Table 8). Adjusted 
logistic regression results showed a positive but non-significant association between low GWG 
and LBW (aOR 1.49, 95% CI 0.61-3.63) and negative but non-significant association with high 
GWG (aOR 0.86, 95% CI 0.20-3.64) compared to adequate GWG (Table 4). On the other hand, 
women with low GWG had a lower incidence of HBW (3%) compared to those with adequate 
(8%) and high GWG (5%) (Supplement Table 8). Adjusted logistic regression results showed 
a significant negative association between HBW and low GWG (aOR 0.26, 95% CI 0.08-0.84) 
but non-significant association with high GWG (aOR 0.67, 95% CI 0.12-3.62) compared to 
adequate GWG (Table 4).  
 
With regards to size for gestational age, women with low GWG had a higher incidence of SGA 
(17%) compared to those with adequate (12%) and high GWG (14%) (Supplement Table 8). 
Adjusted logistic regression results showed a positive but non-significant association between 
low GWG and SGA (aOR 1.31, 95% CI 0.61-2.80) and between high GWG and SGA (aOR 
1.17, 95% CI 0.38-3.57) compared to adequate GWG (Table 4). On the other hand, women 
with low GWG had a lower incidence of LGA (5%) compared to those with adequate (15%) 
and high GWG (11%) (Supplement Table 8). Adjusted logistic regression results showed a 
significant negative association between low GWG and LGA (aOR 0.29, 95% CI 0.12-0.70) 
but non-significant association in women with high GWG (aOR 0.85, 95% CI 0.27-2.74) 
compared to adequate GWG (Table 4).   
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Table 4. Multivariate association of adverse birth outcomes with low and high GWG compared 
to adequate GWG among HIV-infected women (n = 364). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*p-value less than 0.05  
aOR – Odds ratio 
Preterm model – logistic regression: adjusted for maternal age, education, GA at enrolment, parity, 
prior PTD, ART status 
Birth weight model – multinomial logistic regression: adjusted for maternal age, education, GA at 
enrolment, parity, ART status 
Size for GA model – multinomial logistic regression: adjusted for maternal age, education, GA at 
enrolment, parity, ART status 
 
 
 
 
 
 
 
 
 
 
 
 
 Total (n = 364) 
GWG  
 Low 
n = 235 
High 
n = 44 
 aOR (95% CI) p-value aOR (95% CI) p-value 
GA (weeks)     
Preterm (<37) 1.37 (0.39-4.82) 0.626 0.45 (0.09-2.24) 0.332 
     
Birth weight (g)     
Low (<2500) 1.49 (0.61-3.63) 0.381 0.86 (0.20-3.64) 0.838 
High (≥4000) 0.26 (0.08-0.84) 0.024* 0.67 (0.12-3.62) 0.640 
     
Size for GA     
Small (<10th) 1.31 (0.61-2.80) 0.482 1.17 (0.38-3.57) 0.787 
Large (>90th) 0.29 (0.12-0.70) 0.006* 0.85 (0.27-2.74) 0.790 
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4. DISCUSSION 
This study investigated the association between high BMI/GWG and adverse birth outcomes 
by HIV and ART status in South African women seeking ANC services at Gugulethu MOU. 
Our data shows high prevalence of obesity (51%) amongst HIV-uninfected and HIV-infected 
women. This prevalence suggests that obesity in South Africa is on the rise when compared to 
the 33.1% found in a similar cohort from another peri-urban area in Cape Town 8 years ago 
(38). In addition, we found high obesity prevalence of 50% in HIV-infected women, supporting 
the growing evidence that suggests increased obesity prevalence amongst HIV-infected women, 
which now mirrors that in the general population (39-41). 
 
Although other scholars reported high risk of PTD in women with obese BMI, particularly 
medically-indicated PTD (20, 22, 42, 43); in this study we found no association by both HIV 
and ART status (Table 3 and Supplement Table 5). These scholars suggest that pre-pregnancy 
conditions such as diabetes and hypertension are responsible for this association. In contrast, 
most women in our cohort delivered at the MOU (66%), a primary care facility operated by 
midwives; indicating that they had no history of medical complications. Our findings are in 
agreement with those reported by Ajen et al.(44) which found no association between obese 
BMI and PTD in the Nigerian cohort. Nonetheless, the PTD incidence (18%) we found was 
higher than the estimated population average of 10% in South Africa (45).  
 
The majority of our women did not meet the IOM recommended guidelines for weight gain. 
Our data shows that both low and high GWG had no association with PTD in HIV-infected 
women. However, other studies found that low and high GWG is associated with PTD (22, 46). 
The three GWG categories of low, adequate and high used in this study are based on IOM 
ranges which are linked to pre-pregnancy BMI (35, 47, 48). The absence of an association in 
our cohort may be due to the small sample size for the subset of women that were used for 
GWG analysis. However, there has been controversy regarding the applicability of IOM 
guidelines for GWG in African setting as they were formulated using data obtained from US 
population (35, 49, 50). 
 
With regards to birth weight, overall obese BMI was significantly associated with reduced 
likelihood of having LBW and SGA infants as also seen elsewhere (19, 20, 51). Similar effect 
was observed for obese HIV-infected women though to a lesser extent when compared to obese 
HIV-uninfected women (Table 2). These findings were expected because one of the 
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mechanisms for LBW and SGA infants in pregnant women that have been proposed by other 
authors is poor maternal nutrition resulting in insufficient nutrients available to the foetus and 
poor development (21, 52). Considering that obesity is a condition characterised by excessive 
accumulation of body fat, it is reasonable to speculate that women with obese BMI are not 
likely to lack nutrients needed for foetal development. Although many studies have reported 
HIV infection and/or ART use in pregnancy to be associated with LBW/SGA (28, 30, 53-55), 
only one study has investigated the combined impact of both obesity and HIV infection on 
adverse birth outcomes.  
 
In that study Anderson et al.(56) found increased incidence of LBW infants in obese HIV-
infected women compared to obese HIV-uninfected women as was also observed in this current 
study (Table 2). However, in Anderson et al study, the population was that of women from an 
area with highly ambient air polluted which may have confounded the association (57). In 
addition, in our study we further showed that obese women who initiated ART during 
pregnancy have a lower incidence of LBW/SGA compared to those who initiated before 
pregnancy. These findings are also plausible and in agreement with those found in the Botswana 
cohort where women who initiated ART before pregnancy had worse outcomes compared to 
those who recently initiated ART during pregnancy (27). The mechanism of LBW/SGA 
induced by long term use of ART was proposed in a study which found that high doses of 
tenofovir in utero reduces levels of insulin-like growth factor-1 (IGF-1) and restrict intrauterine 
growth (58, 59). Therefore, the higher incidence of LBW/SGA observed in obese HIV-infected 
women was probably due to LBW promoting effects of ART in those that initiated ART before 
pregnancy. Interestingly, growing evidence suggests that LBW/SGA infants tend to undergo 
‘catch up growth’ in early life which increases the risk of developing obesity, type 2 diabetes 
and cardiovascular diseases later in life (60-64). 
 
The total incidence of HBW, also referred to as macrosomia was 5% in our study, this is higher 
than the previously reported prevalence of 3.4% in South Africa (65) and from other African 
countries (66, 67). This increase may be partly attributed to a significant increase in obesity 
prevalence. In support of this, our findings show that women with obese BMI are almost twice 
as likely to have macrosomic and LGA infants compared to normal BMI women (Table 3) as 
reported in other studies conducted in Africa (11, 13, 68, 69). Although this association 
remained positive in obese HIV-infected women, it was to a lesser extent compared to obese 
HIV-uninfected women, possibly due to the opposite impact of HIV infection/ART-use on birth 
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weight (28, 30, 53-55). This was also reflected when we restricted the analysis to HIV-infected 
women by timing of ART initiation; obese women who initiated ART during pregnancy were 
more likely to have LGA infants compared to those who initiated ART before pregnancy 
(Supplement Table 5), corroborating the implicated birth weight-lowering effect of long term 
ART use in those that initiated ART before pregnancy (Figure 2D). Although there seem to be 
differences in the risks of SGA and LGA infants by ART initiation status where initiating ART 
before pregnancy increases the risk of SGA and initiating ART during pregnancy increases the 
risk of LGA, focusing the analysis to SGA and LGA frequencies in different groups of women 
shows a high risk of both morbidities in obese women, regardless of ART initiation status 
(Figure 2). 
 
Our findings regarding the positive association between obese BMI and macrosomia and LGA 
in HIV-uninfected and HIV-infected women are parallel to those of other authors (7, 8, 33, 67, 
70). Although we did not measure maternal glucose and lipids, the previously proposed 
mechanism for the influence of maternal obesity on foetal growth is gestational diabetes 
mellitus characterised by insulin resistance which leads to increased maternal glucose and 
triglycerides (71). Since maternal blood is passed to the foetus via the placenta, the foetus also 
experiences high levels of insulin, glucose and triglycerides which all promote foetal 
overgrowth (72-74). Macrosomic/LGA infants are likely to become obese in their childhood 
and this predisposes them to diabetes mellitus and metabolic syndrome (15-17). 
 
Although other studies report that high GWG increase the likelihood of having a macrosomic 
or LGA infants, this was not observed in our study, probably due to the small sample size for 
the subset of women in which this analysis was performed. However, we showed that HIV-
infected women with low gestational weight gain are less likely to have LGA infants compared 
to those who gained the recommended weight (Table 4). This result is similar to the findings 
that were reported by Vesco et al. (75) in HIV-uninfected women. Exclusion of 12% and 21% 
of women that had missing data for BMI and GWG (21% participants who did not have weight 
measurement at the third trimester visit, some of them due to early delivery before their third 
trimester study visit), respectively, may have resulted in selection bias and therefore our 
findings should be interpreted with caution. In addition, absence of broader demographic 
information such as education and SES for the overall cohort poses a potential for unmeasured 
confounding in our results. Our investigations were conducted in a cohort of women presenting 
for first ANC visit at varying gestations and therefore we could not measure pre-pregnancy 
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BMI. However, for the longitudinal subset cohort of HIV-infected women, we obtained first 
trimester BMI because of the study design. First trimester BMI is considered a proxy for pre-
pregnancy BMI as weight change in early pregnancy is negligible (76, 77). Using the subset 
cohort as a comparison group, we conducted sensitivity analysis to assess the extent of 
exaggeration of BMI distribution in the overall cohort. We found that restricting the analysis of 
baseline BMI distribution by trimester at first ANC visit in the overall cohort provides similar 
baseline BMI prevalence as the subset cohort. Therefore, our findings are meaningful and they 
reflect the challenge of late presentation for first ANC visit in our setting, which needs to be 
considered when designing interventions targeted at minimising GWG to avert adverse birth 
outcomes. 
 
5. CONCLUSION 
In overall, our results show negative association between high BMI and LBW and SGA when 
compared to normal BMI women regardless of HIV status. However, this effect should not be 
considered as entirely positive because it is paralled by an adverse outcome of HBW and LGA 
infants. Besides, a closer look at obese HIV-infected women shows a burden of both LBW/SGA 
and LGA, regardless of ART initiation status. Therefore, HIV care programs need to 
incorporate management strategies for women with high body mass index to minimise adverse 
infant outcomes. 
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1. MANUSCRIPT SUPPLEMENTAL MATERIAL 
Table 1a. Maternal baseline characteristics of enrolled participants with live singleton births by 
BMI (n = 2779) 
  BMI (n = 2779)  
 Total 
n = 2779  
Normal 
n = 556 
Overweight 
n = 807 
Obese 
n = 1416 
Chi2 
p- value 
Age (years)     <0.001* 
<20 273 (10) 102 (18) 99 (12) 72 (5)  
20-24 604 (22) 158 (28) 196 (24) 250 (18)  
25-29 786 (28) 150 (17) 227 (28) 409 (29)  
30-34 700 (25) 113 (20) 191 (24) 396 (28)  
≥35 416 (15) 33 (6) 94 (12) 289 (20)  
Median (IQR) 28 (23-32) 25 (21-30) 27 (23-32) 29 (25-34)  
      
Height (cm)     0.363 
≤155 939 (34) 177 (32) 263 (33) 499 (35)  
156-161 1053 (38) 217 (39) 300 (37) 536 (38)  
≥162 787 (28) 162 (29) 244 (30) 381 (27)  
Median (IQR) 158  
(154-162) 
158  
(155-162) 
158  
(154-163) 
158 
 (154-162) 
 
      
Obstetric      
GA (weeks)     0.002* 
1st trimester (≤13) 712 (26) 156 (28) 187 (23) 369 (26)  
2nd trimester (14-28) 1598 (58) 330 (59) 469 (58) 799 (56)  
3rd trimester (>28) 406 (15) 53 (10) 129 (16) 224 (16)  
Median (IQR) 19 (13-25) 18 (13-23) 20 (14-26) 20 (13-25)  
Missing  63 (2) 17 (3) 22 (3) 24 (2)  
      
Gravidity      <0.001* 
1 673 (24) 202 (36) 226 (28) 245 (17)  
2 951 (34) 197 (35) 281 (35) 473 (33)  
≥3 1148 (41) 155 (28) 298 (37) 695 (49)  
Median (IQR) 2 (2-3) 2 (1-3) 2 (1-3) 2 (2-3)  
Missing  7 (0.3) 2 (0.4) 2 (0.3) 3 (0.2)  
      
Parity     <0.001* 
0 822 (30) 252 (45) 274 (34) 296 (21)  
1 1038 (37) 194 (35) 291 (36) 553 (39)  
≥2 911 (33) 108 (19) 240 (30) 563 (40)  
Median (IQR) 1 (0-2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    1 (0-1) 1 (0-2) 1 (1-2)
Missing 8 (0.3) 2 (0.4) 2 (0.3) 4 (0.3)  
      
Prior preterm#     <0.001* 
Yes 200 (7) 36 (6) 57 (7) 107 (8)  
No 1684 (61) 255 (46) 468 (58) 961 (68)  
Missing  895 (32) 265 (48) 282 (35) 348 (25)  
      
Prior pregnancy loss#     <0.001* 
Yes  333 (12) 75 (13) 81 (10) 177 (13)  
No 1645 (59) 252 (45) 469 (58) 924 (65)  
Missing  801 (29) 229 (41) 257 (32) 315 (22)  
*p-value less than 0.05  
 #Among women with a previous pregnancy 
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Table 1b. Maternal baseline characteristics of enrolled HIV-infected participants with live 
singleton births by BMI and ART status (n =1080) 
 
*p-value less than 0.05  
#Amongst women with a previous pregnancy
  ART initiation during pregnancy 
n = 541 
 ART initiation before pregnancy  
n = 539 
 
  
Total 
n = 1080  
BMI  
Chi2 
p-value  
BMI  
Chi2 
p-value Normal  n = 120 
Overweight 
n = 146 
Obese 
n = 275 
Normal  
n = 100 
Overweight 
n = 169 
Obese 
n = 270 
Age (years)     <0.001*    0.004* 
<20 53 (5) 9 (8) 14 (10) 14 (5)  7 (7) 4 (2) 5 (2)  
20-24 155 (14) 34 (28) 16 (11) 38 (14)  12 (12) 30 (18) 25 (9)  
25-29 304 (28) 41 (34) 48 (33) 95 (35)  28 (28) 36 (21) 56 (21)  
30-34 357 (33) 33 (28) 49 (34) 89 (32)  36 (36) 56 (33) 94 (35)  
≥35 211 (20) 3 (3) 19 (13) 39 (14)  17 (17) 43 (25) 90 (33)  
Median (IQR) 30 (25-33) 26 (23-30) 29 (25-32) 29 (25-32)  30 (25-33) 31 (26-35) 32 (28-35)  
          
Height (cm)     0.032*    0.960 
≤155 364 (34) 33 (28) 43 (29) 112 (41)  36 (36) 53 (31) 87 (32)  
156-161 366 (34) 35 (29) 52 (36) 82 (30)  34 (34) 63 (37) 100 (37)  
≥162 311 (29) 42 (35) 44 (30) 72 (26)  28 (28) 50 (30) 75 (28)  
Median (IQR) 158  
(154-163) 
159  
(154-163) 
158  
(154-163) 
157  
(153-162) 
 158 
(154-163) 
159  
(154-162) 
158  
(154-162) 
 
Missing 39 (4) 10 (8) 7 (5) 9 (3)  2 (2) 3 (2) 8 (2)  
          
Obstetrics          
GA (weeks)     0.157    0.582 
1st trimester (≤13) 331 (31) 35 (29) 27 (18) 75 (27)  37 (37) 60 (36) 97 (36)  
2nd trimester (14-28) 578 (54) 67 (56) 88 (60) 151 (56)  51 (51) 83 (49) 138 (51)  
3rd trimester (>28) 144 (13) 12 (10) 26 (18) 43 (43)  9 (9) 25 (15) 29 (11)  
Median (IQR) 18 (12-25) 18 (12-22) 20 (15-27) 19 (13-25)  17 (12-20) 18 (12-25) 17 (12-24)  
Missing  27 (3) 6 (5) 5 (3) 6 (2)  3 (3) 1 (1) 6 (2)  
          
Gravidity      <0.001*    0.436 
1 181 (17) 34 (28) 32 (22) 37 (13)  17 (17) 30 (18) 31 (11)  
2 375 (35) 53 (44) 46 (32) 96 (35)  36 (36) 56 (33) 88 (33)  
≥3 518 (48) 32 (27) 67 (46) 141 (51)  46 (46) 82 (49) 150 (56)  
Median (IQR) 2 (2-3) 2 (1-3) 2 (2-3) 3 (2-3)  2 (2-3) 2 (2-3) 3 (2-3)  
Missing  6 (1) 1 (1) 1 (1) 1 (0.4)  1 (1) 1 (1) 1 (0.4)  
          
Parity     0.001*    0.033* 
0 242 (22) 44 (37) 37 (25) 49 (18)  25 (25) 45 (27) 42 (16)  
1 427 (40) 51 (43) 53 (36) 119 (43)  43 (43) 53 (31) 108 (40)  
≥2 404 (37) 24 (20) 55 (38) 105 (38)  31 (31) 70 (41) 119 (44)  
Median (IQR) 1 (1-2) 1 (0-1) 1 (0-2) 1 (1-2)  1 (0-2) 1 (0-2) 1 (1-2)  
Missing 7 (1) 1 (1) 1 (1) 2 (1)  1 (1) 1 (1) 1 (0.4)  
          
Prior preterm#     0.026*    0.538 
Yes 94 (9) 13 (10) 13 (9) 20 (7)  8 (8) 17 (10) 23 (9)  
          
Prior pregnancy loss#     0.115    0.353 
Yes  163 (15) 14 (12) 18 (12) 47 (17)  21 (21) 23 (14) 40 (15)  
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Table 2. Incidence of adverse birth outcomes by BMI among women with live singleton births 
(n = 2779) 
  
Total 
n = 2779 
BMI (n = 2779) Chi2 
 p-value Normal 
n = 556 
Overweight 
n = 807 
Obese 
n = 1416 
GA (weeks)     0.138 
Preterm (<37) 494 (18) 105 (19) 141 (17) 248 (18)  
Term (≥37) 2237 (81) 439 (79) 646 (80) 1152 (81)  
Missing 48 (2) 12 (2) 20 (2) 16 (1)  
      
Birth weight (g)     <0.001* 
Low (<2500) 321 (12) 92 (17) 92 (11) 137 (10)  
Normal (2500 - 3999) 2323 (84) 446 (80) 686 (85) 1191 (84)  
High (≥4000) 125 (5) 16 (3) 25 (3) 84 (6)  
Mean (SD) 3132 (578) 2987 (580) 3102 (567) 3206 (572)  
Missing 10 (0.4) 2 (0.4) 4 (0.5) 4 (0.3)  
      
Size for GA     <0.001* 
Small (<10th) 343 (12) 90 (16) 118 (15) 135 (10)  
Appropriate (10-90th) 1918 (69) 390 (90) 549 (68) 979 (69)  
Large (>90th) 371 (13) 46 (8) 89 (11) 236 (17)  
Missing 147 (5) 30 (5) 51 (6) 66 (5)  
 
 
Table 3. Incidence of adverse birth outcomes by BMI and ART status among HIV-infected 
women with live singleton births (n = 1080) 
 HIV-infected  
n =1080 
 
 ART initiation during 
pregnancy 
n = 541 
 ART initiation before pregnancy  
n = 539 
 
 BMI  
Chi2 
p-value 
BMI  
Chi2 
p-value 
Normal  
n = 120 
Overweight 
n = 146 
Obese 
n = 275 
Normal  
n = 100 
Overweight 
n = 169 
Obese 
n = 270 
GA (weeks)    0.363    0.420 
Preterm (<37) 27 (23) 27 (18) 46 (17)  22 (22) 25 (15) 59 (22)  
Term (≥37) 90 (75) 116 (79) 227 (83)  77 (77) 143 (85) 209 (77)  
Missing 3 (2.5) 3 (2) 2 (0.7)  1 (1) 1 (1) 2 (1)  
         
Birth weight (g)    0.021*    0.129 
Low (<2500) 26 (22) 20 (14) 29 (11)  21 (21) 14 (8) 37 (14)  
Normal (2500 - 3999) 90 (75) 121 (83) 224 (81)  75 (75) 148 (88) 224 (83)  
High (≥4000) 4 (3) 3 (2) 19 (7)  3 (3) 5 (3) 8 (3)  
Mean (SD) 2868 
(631) 
3058  
(589) 
3182 
(612) 
 2919 
(615) 
3101  
(475) 
3070 
(564) 
 
Missing 0 2 (1) 3 (1)  1 (1) 2 (1) 1 (0.4)  
         
Size for GA    0.027*    0.412 
Small (<10th) 18 (15) 27 (18) 28 (10)  22 (22) 32 (19) 37 (14)  
Appropriate (10-90th) 91 (76) 103 (71) 196 (71)  62 (62) 113 (67) 185 (69)  
Large (>90th) 6 (5) 12 (8) 40 (15)  13 (13) 16 (9) 37 (14)  
Missing 5 (4) 4 (3) 11 (4)  3 (3) 8 (5) 11 (4)  
*p-value less than 0.05  
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Table 4. Adjusted odds of adverse birth outcomes among women with high BMI compared to 
normal BMI (n = 2779) 
*p-value less than 0.05
Preterm model – logistic regression: adjusted for maternal age, GA at enrolment, parity, prior PTD, 
HIV infection 
Birth weight model – multinomial logistic regression: adjusted for maternal age, GA at enrolment, 
parity, HIV infection  
Size for GA model – multinomial logistic regression: adjusted for maternal age, GA at enrolment, 
parity, HIV infection 
BMI 
Overweight 
n = 807 
Obese 
n = 1416 
aOR (95% CI) p-value aOR (95% CI) p-value
GA (weeks) 
Preterm (<37) 1. 05 (0.72-1.52) 0.814 1.06 (0.75-1.49) 0.739
Birth weight (g) 
Low (<2500) 0.64 (0.47-0.89) 0.008* 0.53 (0.39-0.72) <0.001* 
High (≥4000) 1.03 (0.53-1.99) 0.932 2.00 (1.13-3.57) 0.018* 
Size for GA 
Small (<10th) 0.87 (0.64-1.18) 0.373 0.55 (0.41-0.75) <0.001* 
Large (>90th) 1.33 (0.91-1.95) 0.141 1.98 (1.40-2.80) <0.001* 
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        Table 5. Adjusted odds of adverse birth outcomes by ART status among HIV-infected women with high BMI compared to normal BMI (n = 1080) 
*p-value less than 0.05
Preterm model – logistic regression: adjusted for maternal age, GA at enrolment, parity, prior PTD
Birth weight model – multinomial logistic regression: adjusted for maternal age, GA at enrolment, parity
Size for GA model – multinomial logistic regression: adjusted for maternal age, GA at enrolment, parity
All outcomes adjusted for maternal age, height, GA at enrolment, parity, prior PTD
HIV-infected n = 1080 
ART initiation during pregnancy 
n = 541 
ART initiation before pregnancy 
n = 539 
BMI BMI 
Overweight 
n = 146 
Obese 
n = 275 
Overweight 
n = 169 
Obese 
n = 270 
aOR (95% CI) p-value aOR (95% CI) p-value aOR (95% CI) p-value aOR (95% CI) p-value
GA (weeks) 
Preterm (<37) 0.79 (0.36-1.73) 0.551 1.03 (0.50-2.11) 0.937 1.94 (0.91-4.13) 0.088 1.01 (0.53-1.93) 0.979 
Birth weight (g) 
Low (<2500) 0.65 (0.33-1.30) 0.225 0.51 (0.27-0.94) 0.032* 0.33 (0.15-0.69) 0.003* 0.56 (0.30-1.04) 0.067 
High (≥4000) 0.65 (0.14-3.03) 0.582 2.10 (0.68-6.48) 0.194 0.70 (0.16-3.07) 0.635 0.71 (0.18-2.83) 0.627 
Size for GA 
Small (<10th) 1.12 (0.57-2.22) 0.737 0.65 (0.34-1.26) 0.201 0.74 (0.39-1.39) 0.349 0.53 (0.29-0.99) 0.047* 
Large (>90th) 1.89 (0.67-5.31) 0.229 3.26 (1.32-8.09) 0.011* 0.64 (0.29-1.43) 0.276 0.87 (0.43-1.78) 0.710 
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Table 6. Maternal baseline characteristics of HIV-infected women with live singleton births by 
BMI (n = 364) 
*p-value less than 0.05;
Total 
n = 364 
BMI 
Chi2 
p-value
Normal 
n = 91 
Overweight 
n = 107 
Obese 
n = 166 
Age (years) 0.224 
<20 16 (4) 5 (5) 5 (5) 6 (4) 
20-24 46 (13) 16 (18) 15 (14) 15 (9) 
25-29 110 (30) 33 (36) 32 (30) 45 (27) 
30-34 110 (30) 23 ()25 32 (30) 55 (33) 
≥35 82 (23) 14 (15) 23 (22) 45 (27) 
Median (IQR) 30 (26-34) 28 (25-33) 30 (26-33) 31 (28-35) 
In a relationship 0.800 
Yes 356 (98) 88 (97) 106 (99) 162 (98) 
No 6 (2) 2 (2) 1 (1) 3 (2) 
Missing 2 (0.5) 1 (1) 0 1 (0.6) 
Completed High 
School 
0.239 
Yes 100 (27) 30 (33) 30 (28) 40 (24) 
No  263 (72) 60 (66) 77 (72) 126 (76) 
Missing 1 (0.3) 1 (1) 0 0 
Employed 0.914 
Yes 161 (44) 39 (43) 49 (46) 73 (44) 
No 203 (56) 52 (57) 58 (54) 93 (56) 
Height (cm) 0.476 
≤155 86 (24) 21 (23) 27 (25) 38 (23) 
156-161 141 (39) 36 (40) 34 (32) 71 (43) 
≥162 137 (38) 34 (37) 46 (43) 57 (34) 
Median (IQR) 160 (156-164) 160 (156-165) 161 (156-165) 160 (156-163) 
GA at enrolment 
(weeks) 
Median (IQR) 15 (12-18) 15 (12-18) 15 (12-18) 14 (11-18) 0.633 
Gravidity  0.004* 
1 66 (18) 25 (27) 18 (17) 23 (14) 
2 126 (35) 36 (40) 41 (38) 49 (30) 
≥3 172 (47) 30 (33) 48 (45) 94 (57) 
Median (IQR) 2 (2-3) 2 (1-3) 2 (2-3) 3 (2-3) 
Parity 0.029* 
0 90 (25) 33 (36) 25 (23) 32 (19) 
1 159 (44) 38 (42) 46 (43) 75 (45) 
≥2 115 (32) 20 (22) 36 (34) 59 (36) 
Median (IQR) 1 (1-2) 1 (0-1) 1 (1-2) 1 (1-2) 
Prior preterm# 0.190 
Yes 32 (9) 9 (10) 8 (7) 15 (9) 
Prior pregnancy loss# 0.025* 
Yes  69 (19) 11 (12) 15 (14) 43 (26) 
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#Among women with a previous pregnancy
Table 7. Proportion of HIV-infected women with low, adequate and high GWG within each 
BMI category based on IOM’s GWG guidelines (n = 364) 
Table 8. Incidence of adverse birth outcomes by GWG among HIV-infected women with live 
singleton births (n = 364) 
*p-value less than 0.05
IOM GWG 
guidelines 
Total (kg) 
GWG (n = 364) 
Chi2 
p-value
Low 
n = 235 
Adequate 
n = 85 
High 
n = 44 
BMI (kg/m2) <0.001* 
Normal (18.5-24.9) 11.5 – 16 76 (84) 11 (12) 4 (4) 
Overweight (25-29.9) 7 – 11.5 69 (64) 29 (27) 9 (8) 
Obese (≥30) 5-9  90 (54) 45 (27) 31 (19) 
Total 
n = 364 Chi2 
p-valueGWG 
Total 
n = 364 
Low 
n = 235 
Adequate 
n = 85 
High 
n = 44 
GA (weeks) 0.902 
Preterm (<37) 27 (7) 17 (7) 6 (7) 4 (9) 
Term (≥37) 337 (93) 218 (93) 79 (93) 40 (91) 
Birth weight (g) 
Low (<2500) 39 (11) 29 (12) 7 (8) 3 (7) 0.253 
Normal (2500 - 3999) 308 (85) 198 (84) 71 (84) 39 (89) 
High (≥4000) 15 (4) 6 (3) 7 (8) 2 (5) 
Mean (SD) 3122 (508) 3062 (495) 3264 (512) 3160 (522) 
Missing 2 (0.5) 2 (1) 0 0 
Size for GA 0.025* 
Small (<10th) 57 (16) 41 (17) 10 (12) 6 (14) 
Appropriate (10-90th) 278 (76) 183 (78) 62 (73) 33 (75) 
Large (>90th) 29 (8) 11 (5) 13 (15) 5 (11) 
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